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1.1. The phosphatidylinositol 3-kinases (PI3Ks) family 
The phosphatidylinositol 3-kinases (PI3Ks) are members of a unique and conserved family 
of intracellular lipid kinases. Since its discovery in the 1980s, this family of lipid kinases 
has been found to have key regulatory roles in many cellular processes, including cell 
survival, proliferation and differentiation. PI3Ks phosphorylate the 3′-hydroxyl group of 
phosphatidylinositol and phosphoinositides and this reaction leads to the activation of 
many intracellular signaling pathways that regulate functions as diverse as cell 
metabolism, survival, polarity, and vesicle trafficking. A host of intracellular signaling 
proteins have evolved the ability to bind to the lipid products of PI3Ks and therefore 
become activated by PI3K signaling.  
PI3K first became a focus in the cancer-research field when it became apparent that PI3K 
activity was physically and functionally associated with the transforming activity of viral 
oncogenes, such as the SRC tyrosine kinase and polyomavirus middle T antigen1. Over 
the past decade, it has become evident that the PI3K signaling pathway is one of the most 
highly mutated systems in human cancers, underscoring its central role in human 
carcinogenesis. Indeed, different human cancer genomic studies have revealed that many 
components of the PI3K pathway as well as proteins involved in the negative regulation of 
the pathway are frequently targeted by mutations or functional inactivation in a broad 
range of human cancers. These findings, and the fact that PI3K and other kinases in the 
PI3K pathway are amenable to pharmacological intervention, make this pathway one of 
the most attractive targets for therapeutic intervention in cancer2. 
 
1.1.1. PI3Ks classification 
PI3Ks are grouped into three classes (I–III) according to their structural characteristics and 
substrate specificity (Figure 1). In mammals, numerous genes encode different isoforms of 
PI3Ks. All PI3K isoforms are widely expressed, with the exception of the class IA p55γ 
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subunit, which is enriched in the brain and the testes, and the p110δ subunit, which is 
predominantly expressed in lymphocytes. p110γ is mainly expressed in lymphocytes but is 
also found in the heart, pancreas, liver and skeletal muscle3-4. 
 
Class I PI3Ks. Class I PI3Ks are divided into two subfamilies, depending on the receptors 
to which they couple.  
Class IA PI3K is a heterodimer that consists of a p85 regulatory subunit and a p110 
catalytic subunit. In mammals, there are numerous isoforms of each subunit. Three genes, 
PIK3R1, PIK3R2 and PIK3R3 (PI3K regulatory subunit 1, -2 and -3), encode the p85α, 
p85β and p55γ isoforms of the p85 regulatory subunit, respectively. The PIK3R1 gene also 
gives rise to two shorter isoforms, p55α and p50α, through alternative transcription-
initiation sites. All these splice variants make functional complexes with p110 subunits. 
p110α and p110β are widely distributed in mammalian tissues, in contrast to p110δ, which 
shows a more restricted distribution and is mainly found in leukocytes5. The class IA p85 
regulatory isoforms have a common core structure consisting of a p110-binding domain 
(also called the inter-SH2 domain) flanked by two Src-homology 2 (SH2) domains. The two 
longer isoforms, p85α and p85β, also have an extended N-terminal region containing an 
Src-homology 3 (SH3) domain and a BCR homology (BH) domain flanked by two proline-
rich (P) regions6. The p85 regulatory subunit mediate the activation of class IA PI3K by 
receptor tyrosine kinases (RTKs). The SH2 domains of p85 bind to phospho-tyrosine 
residues in the sequence context phospho-YXXM on activated RTKs or adaptor molecules 
(such as IRS1). This binding both relieves the basal inhibition of p110 by p85 and recruits 
the p85–p110 heterodimer to its substrate (PtdIns(4,5)P2) at the plasma membrane
3. The 
p110 catalytic subunit isoforms, p110α, p110β and p110δ, are encoded by three different 
genes PIK3CA, PIK3CB and PIK3CD, respectively. They possess an N-terminal p85-
binding domain that interacts with the p85 regulatory subunit, a Ras-binding domain (RBD) 
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that mediates activation by the small GTPase Ras, a C2 domain, a phosphatidylinositol 
kinase homology (PIK) domain and a C-terminal catalytic domain. The PIK and catalytic 
domains of p110 are homologous to domains found in a family of protein kinases that 
includes mTOR (mammalian target of rapamycin), ATM (ataxia telangiectasia mutated), 
ATR (ataxia telangiectasia Rad3 related) and DNA-PK (DNA-dependent serine/threonine 
protein kinase), indicating that these proteins share an ancient evolutionary origin3. 
Class IB PI3Ks are heterodimers consisting of a p101 regulatory subunit and a p110γ 
catalytic subunit. Although p110γ shares extensive homology with the class IA p110 
proteins, p101 is distinct from p85 proteins. Two other regulatory subunits of class IB 
PI3Ks, p84 and p87 PI3K adaptor proteins, have also been described7-8. 
In vivo, class I PI3Ks primarily generate PtdIns(3,4,5)P3 from PtdIns(4,5)P2
3
 (Figure 2 A 
and B). 
 
Class II PI3Ks. Members of this class consist of a single p110-like catalytic subunit. There 
are three class II PI3K catalytic isoforms, the ubiquitously expressed PI3KC2α and 
PI3KC2β and liver-specific PI3KC2γ. These catalytic isoforms are encoded by distinct 
genes. All three isoforms share significant sequence homology with the class I p110 
subunits. In addition, class II PI3Ks have an extended divergent N terminus, and additional 
PX and C2 domains at the C terminus. However, the specific cellular functions of this 
family is still unclear3-4.  
Class II PI3Ks preferentially use PtdIns or PtdIns(4)P as substrates to generate PtdIns(3)P 
and PtdIns(3,4)P2 in vitro, and might generate PtdIns(3)P, PtdIns(3,4)P2 and possibly 
PtdIns(3,4,5)P3 in vivo
3-4 (Figure 2 A). 
 
Class III PI3Ks. Class III PI3Ks consist of a single member and are the homolog of the 
yeast vesicular-protein-sorting protein Vps34p. The catalytic member Vps34p binds Vps15 
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(also known as PIK3R4 in mammals). Vps15 consists of a catalytic domain (which is 
thought to be inactive), HEAT domains (which probably mediate protein–protein 
interactions) and WD repeats, which have structural and functional characteristics similar 
to a Gβ subunit. The WD repeats are essential for interaction with RAB5–GTP141 and the 
yeast guanine nucleotide-binding protein 1a (Gpa1; the homologue of the mammalian Gα 
of heterotrimeric G proteins) and autophagy‑related protein 14 (Atg14; a potential Gγ 
protein)9. In vitro, these PI3Ks can use only PtdIns as a substrate, and in vivo they only 
produce PtdIns(3)P from PtdIns which is an important regulator of membrane trafficking3 
(Figure 2 A). Class III PI3Ks are likely to be responsible for the generation of most of the 
PtdIns(3)P in cells. Vps34 has been shown to function as a nutrient‑regulated lipid kinase 
that mediates signaling through mammalian target of rapamycin (mTOR), indicating a 
potential role in regulating cell growth. Interestingly, it has also been implicated as an 
important regulator of autophagy, a cellular response to nutrient starvation10. 
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Figure 1: Classification and domain structure of mammalian PI3Ks
9
. 
 
 
Figure 2: (A) Schematic representation of the substrate preferences of class I, II and III PI3Ks
3
. (B) Class I PI3K phosphorylates 
PtdIns(4,5)P3 producing PtdIns(3,4,5)P3, whereas: the phosphatase PTEN antagonize PI3K signaling
4
. 
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1.1.2. PI3Ks substrates 
Phosphatidylinositol (PtdIns), the basic building block for the intracellular inositol lipids in 
eukaryotic cells, consists of D-myo-inositol-1-phosphate linked via its phosphate group to 
diacylglycerol. The inositol head group of PtdIns has five free hydroxyl groups, three of 
which have been found to be phosphorylated in cells, in different combinations. PtdInsPs 
all reside in membranes and are substrates for kinases, phosphatases and lipases 
resident in or recruited to these membranes. The PI3Ks use PtdIns and its phosphorylated 
forms as substrates5. Inositol lipids and inositol phosphates levels in mammalian cells 
have been determined. PtdIns is the most abundant inositol lipid under basal conditions, 
present at levels 10–20 times higher than those of PtdIns(4)P and PtdIns(4,5)P2, which are 
present in roughly equal amounts. Of the total singly phosphorylated PtdIns in cells, 90–
96% is PtdIns(4)P, whereas PtdIns(3)P and PtdIns(5)P each make up about 2–5%. 
PtdIns(4,5)P2 is the most abundant of the doubly phosphorylated PtdIns (>99%); 
PtdIns(3,4)P2 and PtdIns(3,5)P2 each make up about 0.2% of the PtdInsP2. The levels of 
PtdIns(3,4,5)P3 vary enormously but can be comparable to those of PtdIns(3,4)P2 and 
PtdIns(3,5)P2
5. All of these lipid products are membrane-limited, and thus 
compartmentalized allowing a selective action. PtdIns(3,4,5)P3, which activates multiple 
downstream signaling pathways, is mainly produced through class I PI3Ks. PtdIns(3,4,5)P3 
is a lipid with key signaling functions and a major role in the control of cell survival, growth 
and proliferation. 
 
1.1.3. Class I PI3K signaling activation 
PI3K signaling can be activated by multiple stimuli: activated tyrosine kinase growth factor 
receptors; cell adhesion molecules, such as integrins and G-protein-coupled receptors 
(GPCR); and oncogenes, such as Ras. As mentioned above, class IA and IB isoforms 
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differ in the receptors they couple: the first are activated by tyrosine kinase receptors or 
Ras; the latter are activated by heterotrimeric G proteins or Ras3.  
In class IA PI3Ks, p85 subunits provide at least three functions to p110 proteins: 
stabilization, inactivation of their kinase activity in the basal state and recruitment to 
phosphor-Tyr residues in receptors and adaptor molecules. Inactive p85–p110 complexes 
are present in the cytoplasm of resting cells, poised for activation in response to 
appropriate cues. Class IA PI3K can become activated by at least three independent 
pathways, all of which start with binding of ligand to RTKs or to adaptor proteins 
associated with the receptors [for example, insulin receptor substrate 1 (IRS1)]11-12. RTKs 
dimerize and undergo autophosphorylation at tyrosine residues, which allows them to 
interact with SH2-domain-containing molecules. Therefore, the p85–p110 complex is 
recruited to the receptor by interaction of the SH2 domain of p85 with consensus 
phosphotyrosine residues on the RTK or with the IRS1/IRS2 signaling intermediate, in 
some cases. Engagement of the p85 SH2 domains by phosphorylation relieves the 
p85‑mediated inhibition of p110 isoforms and also brings them in contact with their lipid 
substrates in the membrane. In one activation pathway, the 85 kDa regulatory subunit of 
PI3K (p85) binds directly to phospho-YXXM motifs (in which X indicates any amino-acid) 
within the RTK, triggering activation of PI3K’s 110 kDa catalytic subunit (p110)13. Indeed, 
the binding relieves the intermolecular inhibition of the p110 catalytic subunit by p85 and 
localizes PI3K to the plasma membrane where its substrate resides12. Other PI3K 
signaling pathways depend on the adaptor protein GRB2 (growth factor receptor-bound 
protein 2) which binds preferentially to phospho-YXN motifs of the RTK. GRB2 binds to the 
scaffolding protein GAB (GRB2-associated binding protein), which in turn can bind to p85. 
PI3K can also be stimulated by activated Ras, which directly binds p11014. Each of the 
class I PI3K catalytic isoforms has a segment known as the RAS-binding domain (RBD), 
which can induce inputs through Ras or other small GTPases. Ras has a documented role 
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in the activation of p110α and p110γ, whereas a role for Ras in p110β activation is less 
clear, with indirect evidence in favor and against9. Several studies indicate that p110α-
RBD interacts directly with oncogenic RAS, whereas p110β interacts with GTP-bound 
RAC and cell division cycle 42 (CDC42)15. There is also evidence for a role of the Ras 
family member TC21 (also known as RRAS2) upstream of p110δ. TC21 recruits p110δ to 
antigen receptors in lymphocytes and, consistent with this, TC21-null and p110δ-null mice 
have striking similarities in their immunological-phenotypes9. GRB2 activates Ras (through 
the activation of SOS), and Ras activates p110 independently of p85. GRB2 can also exist 
in a large complex that contains both SOS, Ras, and GAB or other scaffolding proteins, 
bringing these activators into close proximity with p110 PI3K13. It is not clear precisely 
which of these pathways predominates in different physiological situations. Additionally, 
the p110β isoform of class IA PI3K is regulated not only by the p85 regulatory subunit but 
also by binding to Gβγ subunits of heterotrimeric G proteins16.Therefore, the class IA 
p110β isoform might integrate signals from GPCRs as well as RTKs. In addition to their 
SH2 domains, which engage class I PI3Ks with Tyr kinase signaling pathways, all p85 
isoforms have a Pro-rich region amino-terminal to the N-SH2 domain. The p85 N-termini 
are distinct for each p85 isoform and might allow additional signaling input and output, the 
roles of which are not well investigated9. For example, p85α (PIK3R1) and p85β (PIK3R2) 
also contain an SH3 domain, a second Pro-rich region and a BCR homology (BH) domain, 
which might have intrinsic GTPase-activating protein (GAP) activity for Rab family 
members9. Related to this, there is some evidence to suggest that p85 isoforms can 
interact with small GTPases (such as Rac, Rho and Cdc42), but this has only been 
investigated for isolated p85, not when p85 is in complex with p1109. 
Class IB PI3K do not comprise p85 family regulatory subunits and therefore are not 
regulated by RTKs. G protein-coupled receptors (GPCRs) directly stimulate p110γ through 
interacting directly with the βγ subunits of heterotrimeric G proteins. The p101 regulatory 
14 
 
subunit facilitates the activation of the p101–p110γ heterodimer by Gβγ4. Moreover, also 
p110γ subunit possess the RAS-binding domain and tyrosine kinases can activate p110γ 
in some cell types via RAS. The Ras family member TC21 (also known as RRAS2) may 
have a role in the activation of p110δ9 and the RBD domain of p110γ is required for PI3K 
signaling in neutrophils15. 
 
 
 
Figure 3: Upstream signals feeding into class I PI3Ks
9
. 
 
 
1.1.4. The main components of class I PI3K signaling network 
PDK1. PDK1 belongs to the family of AGC kinases (serine and threonine kinases) that 
show a sequence homology in their catalytic domain to cAMP-dependent protein kinase 1, 
cyclic guanosine monophosphate-dependent protein kinase, and protein kinase C (PKC).  
PDK1 was originally discovered in 1997 as the kinase responsible for the phosphorylation 
of the Akt activation loop, at residue Thr308, which is essential for enzyme activation, thus 
linking PDK1 to the upstream activation of PI3K17. PDK1 kinase is a protein of 556 amino 
acids that possesses an N-terminal catalytic domain, a C-terminal PH domain, and a 
nuclear export sequence. The nuclear export sequence is a short sequence of four amino 
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acids that are essential for exporting PDK1 from the cell nucleus to the cytoplasm through 
the nuclear pore complex using nuclear transport18. The amino-terminal small lobe and the 
carboxy-terminal large lobe comprise one adenosine triphosphate molecule essential for 
the subsequent substrate phosphorylation. As many AGC kinases, PDK1 possesses two 
phosphorylation sites that regulate its activation: one in the activation loop, which is 
located within the kinase domain; and another in the hydrophobic motif, which is located in 
a region adjacent to the catalytic domain18. The PDK1 phosphorylation site within the 
activation loop (Ser241) is phosphorylated in resting cells and is not affected by growth 
factor stimulation. The phosphorylation of PDK1 in Ser241 is catalyzed by an 
autophosphorylation reaction in trans19. PDK1 kinase activity is therefore constitutively 
active, and the regulation of PDK1-activated signaling involves different mechanisms. The 
phosphorylation of the other sites increases kinase activity and leads to enzymatic full 
activation18. PDK1 localized at the plasma membrane due to the interaction of its PH 
domain with PtdIns(3,4,5)P3, PtdIns(3,4)P2, and PtdIns(4,5)P2 and PDK1 membrane 
localization is essential for Akt phosphorylation in Thr308. PDK1 phosphorylates many 
other kinases, such the serum glucocorticoid-dependent kinase (SGK), ribosomal protein 
S6 kinases 1 (S6K1), p90 ribosomal protein S6 kinase (RSK), and atypical PKC isoforms, 
but the mechanism of activation of these kinases differs from the Akt activation 
mechanism18. 
 
Akt. Akt is a 57 kD Ser/Thr kinase and the cellular homologue of the viral oncoprotein v-
Akt, which is known to be responsible for a type of leukemia in mice20. This protein kinase 
is expressed as three isoforms, Akt1, Akt2 and Akt3,  which are encoded by the genes 
PKBα (14q32), PKBβ (19q13.1–13.2) and PKBγ (1q44), respectively21. Akt2 and Akt3 
have 81 and 83% homology in amino acid sequence with Akt1, respectively22. The three 
isoforms share a similar structure consisting in a PH domain in the N-terminus, a central 
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serine–threonine catalytic domain and a C-terminal regulatory domain. The PH domain in 
the N-terminal region of Akt interacts with 3′-phosphoinositides, contributing to recruitment 
of Akt to the plasma membrane. Akt preferentially binds PtdIns(3,4,5)P3 over other PtdIns. 
All three mammalian Akt genes are widely expressed in various tissues, but Akt1 is most 
abundant in brain, heart, and lung, whereas Akt2 is predominantly expressed in skeletal 
muscle and embryonic brown fat, and Akt3 is predominantly expressed in brain, kidney, 
and embryonic heart22. Once PDK1 is activated by PtdIns(3,4,5)P3, it propagates the 
signal to the Ser/Thr kinase Akt by phosphorylating its catalytic domain. Akt activation is 
initiated by translocation to the plasma membrane, which is mediated by docking of the PH 
domain in the N-terminal region of Akt to PtdIns(3,4,5)P3 on the membrane. Thus, 
PtdIns(3,4,5)P3 brings PDK1 and Akt into close proximity. Recruitment to the membrane 
results in a conformational change of Akt that exposes two main phosphorylation sites, 
Thr308 in the kinase domain and Ser473 in the C-terminal regulatory domain. PDK1 
phosphorylates Akt in its activation loop on Thr308, an event that alone stabilize the active 
conformation of Akt and stimulates partial activation21. Phosphorylation of Thr308 is a 
requirement for the activation of Akt, but phosphorylation of the residue located in the 
regulatory domain at C-terminus is required for full activation of the kinase. The 
mammalian target of rapamycin complex 2 (mTORC2) phosphorylates Akt at Ser47323. 
Although if mTORC2 is the primary source for complete Akt activation, several other 
kinases are capable of phosphorylating Akt at Ser473, including PDK1, integrin-linked 
kinase (ILK), an ILK-associated kinase, Akt itself and DNA-dependent protein kinase 
(DNA-PK)21. Phosphorylation of the three Akt isoforms occurs by the same mechanisms. 
The corresponding phosphorylation sites of Akt2 are Thr309 and Ser474, whereas those 
of Akt3 are Thr305 and Ser472. Several evidences have highlighted that Ser473 
phosphorylation precedes Thr308 phosphorylation and actually enhances it24. 
Furthermore, it has been shown that additional phosphorylative steps may increase Akt 
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activation, including phosphorylation of multiple tyrosine residues and phosphorylation on 
Ser129 through casein kinase 2 (CK2), but relevance of these phosphorylative events 
awaits full elucidation24. Akt activity is tightly regulated by several proteins which act by 
phosphorylating other sites. Among these, there is S6K1, a downstream substrate of 
mTOR which plays an important role in negative feedback regulation of Akt by catalyzing 
an inhibitory phosphorylation on IRS proteins, abolishing their association and activation of 
PI3K21. Akt activity is also modulated by a complex network of regulatory proteins that 
interact with the PH domain, or the kinase domain or the C-terminal of Akt. One of these 
proteins is heat-shock protein-90 (HSP-90), a molecular chaperone that forms a complex 
with the co-chaperone Cdc37. This complex binds a variety of proteins, including tyrosine 
and serine/threonine protein kinases. The HSP-90/Cdc37 complex interacts with the Akt 
kinase domain24. 
Once Akt has been phosphorylated and activated, it phosphorylates many other proteins 
regulating a wide range of cellular processes involved in protein synthesis, cell survival, 
proliferation and metabolism. 
 
mTOR. mTOR is an atypical serine/threonine protein kinase that belongs to a group of 
serine–threonine protein kinases of the PI3K superfamily, referred to as class IV PI3Ks, 
including ATM, ataxia telangiectasia and RAD3‑related protein (ATR), DNA‑PK and 
SmG1 (SmG1 homologue, phosphatidylinositol 3‑kinase‑related kinase)4. mTOR exists in 
2 multiprotein complexes: mTOR complex 1 and 2 (mTORC1 and mTORC2). mTORC1 is 
composed of the mTOR catalytic subunit, mammalian LST8, proline-rich Akt1 substrate 40 
(PRAS40), and the regulatory associated protein of mTOR, raptor, whereas mTORC2 
consists of a complex of mTOR, mLST8, mammalian stress-activated protein kinase 
interacting protein (mSIN1), protor, and rictor21.  
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Akt activates mTORC1 through at least 2 mechanisms: either directly by phosphorylating 
mTORC1 at Ser24485025 or indirectly through TSC226. Indeed, one of the key control 
nodes for mTORC1 activity is the TSC complex containing TSC1, TSC2 and TBC1 domain 
family member 7 (TBC1D7) proteins. By phosphorylating TSC2, Akt suppresses the 
inhibitory effect of the TSC complex on mTORC1. A GTPase-activating domain of TSC2 
catalyzes the conversion of the Ras-like protein, Ras homolog enriched in brain (Rheb)-
GTP to Rheb-GDP leading to inactivation of mTOR function. Thus, Akt by decreasing 
TSC2 activity, increases levels of Rheb-GTP, which then leads to activation of mTORC121. 
TSC2 inactivation results in upregulation of mTORC1 activity through a cascade of 
signaling molecules. mTORC1 is a central regulator of cellular metabolism and 
biosynthesis, and is subject to complex regulation by growth factors, nutrients and cellular 
stress. Growth factors, energy sensors and cellular stress converge at the level of the TSC 
complex. Amino acids regulate mTORC1 through the Ragulator and GATOR (GAP activity 
toward RAGs) complexes. mTORC1 promotes anabolic programmes through many 
substrates, including S6K1, eIF4E binding proteins (4E-BPs) and autophagy regulators 
such as UNC51 like kinase 1 (ULK1). When conditions are favorable for cell growth, 
mTORC1 phosphorylates several substrates to promote anabolic processes (such as 
ribosome biogenesis, translation and the synthesis of lipids and nucleotides) and suppress 
catabolic processes (such as autophagy)27. mTORC1 plays a pivotal role in protein 
translation through its substrate: eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) 
and S6K1. Hyperphosphorylation of 4E-BP1 by mTORC1, inhibits its binding to eukaryotic 
initiation factor 4E (eIF4E), thereby activating cap-dependent translation. In addition to 
protein translation, mTORC1 regulates cell proliferation, survival, and angiogenesis by 
regulating eIF4E-mediated translation of Bcl-2, Bcl-xL, and vascular endothelial growth 
factor (VEGF). mTORC1 also phosphorylates S6K1, which in turn leads to phosphorylation 
of S6 ribosomal protein, and other targets, including insulin receptor substrate 1 (IRS1), 
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eukaryotic initiation factor 4B (eIF4B), programmed cell death 4 (PDCD4), eukaryotic 
elongation factor-2 kinase (eEF2K), mTOR, and glycogen synthase kinase-3, which are 
implicated in cellular transformation. In addition, mTORC1 regulates the transition from G1 
to S phase through downregulation of cyclin D1 and c-Myc, which are required for 
progression through this phase of the cell cycle21. mTORC1 activity exerts feedback 
control on growth factor signaling. One canonical feedback pathway is initiated by S6K1, 
that phosphorylates adaptor proteins of the IRS1 family to attenuate growth factor receptor 
signaling to PI3K and RAS. Phosphorylation of IRS1 by S6K1 inhibits IRS1 and thereby 
PI3K activation, forming a negative feedback loop which has an important role in the 
regulation of mTORC128. 
In comparison with mTORC1, less is known about mTORC2 complex. mTORC2 seems to 
have basal activity and is stimulated by association with ribosomes and by growth factors. 
mTORC2 responds to growth factors, such as insulin, through a poorly defined mechanism 
that requires PI3K and ribosomes, as ribosomes are needed for mTORC2 activation and 
mTORC2 binds them in a PI3K-dependent fashion. mTORC2 controls several members of 
the AGC subfamily of kinases, promoting their stability and activity, including Akt, serum-
induced and glucocorticoid-induced protein kinase 1 (SGK1), and protein kinase C alpha 
(PKCα)21. Akt is phosphorylated by mTORC2 at its hydrophobic motif (Ser473), a site 
required for its maximal activation. Indeed, mTORC2 deletion, associated with defective 
Akt-Ser473 phosphorylation, impairs the phosphorylation of some Akt targets. mTORC2 
also directly activates SGK1, a kinase controlling ion transport and growth and mTORC2 
deletion results in complete loss of SGK-1 activity. PKCα is another AGC kinase regulated 
by mTORC2. Along with other effectors, mTORC2 plays a role in cell migration by 
regulating phosphorylation of PKCα and control of the actin cytoskeleton in cell-type-
specific fashion21. 
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PTEN. The PI3K signaling is negative regulated by several phosphatases. The 
Phosphatase and Tensin homolog deleted on chromosome TEN (PTEN) was originally 
identified as a tumor suppressor gene mutated and lost in various cancers and was 
mapped on chromosome 10q2329. Several lines of evidence soon highlighted PTEN as a 
lipid phosphatase-hydrolysing phosphates in position 3’ from phosphoinositides. The major 
function of PTEN is the buffering of PI3K signaling30. PTEN is a dual-specificity 
phosphatase that dephosphorylates both protein and lipid substrates. PTEN preferentially 
removes the 3-phosphate mainly from PtdIns(3,4,5)P3 but is also active on 
PtdIns(3,4,)P2
24. PtdIns(3,4,5)P3 PTEN dephosphorylation forms the inactive 
PtdIns(4,5)P2. Thus, PTEN antagonizes PI3K function and negatively regulates Akt 
activities. The discovery that the tumor suppressor PTEN works by antagonizing PI3K 
established the first direct link between PI3K activation and human cancer. PTEN 
functions as a tumor suppressor by controlling cellular differentiation, inhibiting cell growth 
and enhancing cellular sensitivity to apoptosis13. Loss of PTEN function and its activity in 
cancer occurs through multiple mechanisms, which include mutations, loss of 
heterozygosity, methylation, aberrant expression of regulatory microRNA, protein 
instability, and protein phosphorylation. PTEN is the second most frequently mutated 
tumor suppressor gene and, as shown in multiple studies, it is mutated or deleted in many 
human cancer types, including bladder, breast, prostate, glioblastoma, melanoma and 
endometrial cancers21. PTEN loss-of-function results in Akt upregulation. Therefore, PTEN 
acts as a negative regulator of PI3K/Akt signaling and loss of PTEN activity leads to 
permanent PI3K/Akt pathway activation24. PTEN also acts in the nucleus in a 
phosphatase-independent manner to further impact cell cycle, apoptosis and chromosomal 
integrity31. 
Other mechanisms exist to downregulate PI3K/Akt pathway. The Src-homology 2 (SH2)-
containing phosphatases (SHIP1 and SHIP2) abrogate signaling through PI3K by 
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removing the 5-phosphate and converting PtdIns(3,4,5)P3 to PtdIns(3,4)P2. SHIP1 is 
predominantly expressed in hematopoietic cells whereas SHIP2 is more ubiquitous. 
However, their role on Akt function is not well understood, and in some cases they could 
not reverse Akt activation, something PTEN can do32. Protein phosphatase 2A (PP2A), is 
capable of directly dephosphorylating and downregulating Akt, whereas several work 
indicates that Ser473 phospho-Akt is dephosphorylated by a PP2C family phosphatase, 
referred to as PHLPP24. Furthermore, extensive crosstalk exists with other cellular 
signaling networks to downregulate PI3K signaling pathway, in addition to the control 
exerted by mTOR trough IRS1 downregulation. For example, activation of the tumor 
suppressor p53 causes both increased PTEN and decreased p110 expression. Further, 
p53 degradation is reduced indirectly by PTEN via its antagonism of PI3K. These actions 
safeguard the cell in times of genotoxic strain against ongoing DNA replication, though the 
interplay between p53 and PTEN requires further elucidation33. 
 
1.2. Class I PI3K functions 
The most ancient role for PI3K family of enzymes is probably to mark specific cellular 
membranes for trafficking events, and this seems to be the primary function of the single 
form of PI3K that is found in yeast: Vps34. However, in multicellular eukaryotes, the 
additional isoforms of PI3K have evolved for the dedicated purpose of signal transduction3 
(Figure 4).  
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Figure 4: Signaling through class I PI3Ks
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Cell survival and apoptosis inhibition. Akt could promote growth factor-mediated cell 
survival both directly and indirectly. Akt phosphorylates Bad, a proapoptotic member of the 
Bcl-2 family, at Ser136. This phosphorylation event promotes Bad sequestration by 14-3-3 
proteins in the cytosol, thereby preventing Bad from interacting with either Bcl-2 or Bcl-XL 
at the mitochondrial membrane. The final effect is inhibition of apoptosis34. A similar 
negative regulation has been demonstrated for Yes-associated protein, whose 
phosphorylation by Akt leads to repression of p53-related transcription factor p73 and 
reduced expression of the proapoptotic protein Bax35. Akt may interfere with JNK (Stress-
activated protein kinase/c-Jun N-terminal kinase) signaling. JNK is a MAP kinase activated 
by various cell stimuli, that targets specific transcription factors, thus mediating immediate-
23 
 
early gene expression in response to cell stimuli. JNK has been found required for tumor-
necrosis factor alpha (TNFα) induced apoptosis36. Akt phosphorylate and thereby 
inactivate ASK1, a protein kinase which transduces signals to JNK. Akt also promotes 
phosphorylation and nuclear translocation of Mdm2, an E3 ubiquitin ligase which mediates 
ubiquitinylation and proteasome-dependent degradation of the p53 tumor suppressor 
protein, downregulating p53 and antagonizing p53-mediated cell cycle checkpoint37. Mdm2 
phosphorylation contributes to centrosome hyperamplification and chromosome instability 
in cancer38. Akt also indirectly promote cell survival activating transcription factors that 
upregulate antiapoptotic genes or negatively affecting factors that promote death gene 
expression. For example, Akt phosphorylation of many effectors regulates their localization 
by generating binding sites for 14-3-3 proteins, which are important in regulating cellular 
location and degradation of various molecule. The FoxO family of transcription factors 
functions as a trigger for apoptosis through expression of genes necessary for cell death. 
FoxO proteins are predominantly localized in the nucleus where they are able to promote 
transcription of proapoptotic target genes such as Fas ligand (Fas-L) and Bim. Akt 
phosphorylate FoxO proteins leading to their nuclear export, as phospho-FoxO factors 
specifically interact with 14-3-3 proteins, which serve as chaperone molecules to escort 
them out of the nucleus. Once in the cytoplasm, they are degraded via the ubiquitin-
proteasome pathway39. FoxO factor phosphorylation requires intranuclear localization of 
active Akt. In addition, Akt is capable of upregulating nuclear factor-kappa B (NF-kB), a 
transcription factor which is deeply involved in the regulation of cell proliferation, apoptosis 
and survival. NF-kB induces expression of antiapoptotic proteins including cIAP-1 and -2, 
XIAP, c-FLIP, Bcl-XL, caspase inhibitors and c-Myb. Under non-stimulated conditions, NF-
κB is retained in the cytoplasm trough its association with I-κB. Phosphorylation of I-kB by 
upstream kinases, IKKs, promotes its degradation via the ubiquitin-proteasome pathway. 
This, in turn, allows NF-κB nuclear translocation and upregulation of target genes. Akt 
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phosphorylates directly and activates IKKα and, more importantly, it is believed to be 
essential for IKK-mediated destruction of I-κB24. In addition, Akt phosphorylates and 
activates the cyclic AMP-response element-binding protein, which increases the 
transcription of anti-apoptotic genes, such as those for Bcl-2, Mcl-1, and Akt itself22. 
 
Cell cycle regulation. PI3K pathway activation is required for G1/S progression and PI3K 
inhibition leads to G1 arrest in many cell types, Moreover, PI3K pathway may also regulate 
the efficiency of G2/M phase progression. Cyclin D1 and c-Myc play distinct roles in cell 
cycle progression through G1 phase and their expression is induced early in G1 upon 
growth factor stimulation40.  Cyclin D1 and c-Myc are short-lived proteins whose levels are 
regulated by phosphorylation-dependent proteolytic degradation. Proteolysis of both c-Myc 
and cyclin D1 is regulated by the PI3K pathway. In fact, glycogen synthase kinase 3 beta 
(GSK3β) phosphorylates cyclin D1 at Thr286. This phosphorylation prmoted association of 
cyclin D1 with its nuclear exporter CRM1 and triggered nuclear-cytoplasmic translocation 
leading to ubiquitin-mediated proteolytic degradation of cyclin D1 in the cytoplasm41. The 
activity of GSK3β is inhibited by Akt-dependent phosphorylation, and thus Akt-mediated 
GSK3β inhibition stabilized cyclin D1. The stability of c-Myc is controlled by 
phosphorylation at Ser62 and Thr58, as the first stabilizes c-Myc and the latter creates a 
priming site that is necessary for subsequent phosphorylation by GSK3β at Thr58, which 
appear to activate the ubiquitin dependent degradation of c-Myc. Thus, also in this case, 
Akt stabilizes c-Myc through inhibition of GSK3β42. Akt also promotes transcriptional 
activation of cyclin D1 and c-Myc genes, as well as translation of cyclin D1 mRNA through 
eIF4E42. p27Kip1 is a direct inhibitor of cyclin-dependent kinase (cdk) 2, one of the cdks 
responsible for the activation of E2F1 transcription factors that promote DNA replication43. 
Hight levels of p27Kip1 are required to maintain many cell types in quiescence and, 
therefore, its downregulation is critical for cell cycle progression42. Akt can inactivate 
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p27Kip1 by phosphorylating on Thr157 and inducing its localization in the cytoplasm where it 
cannot exert its inhibitory effect, so that cell proliferation is enhanced44. Moreover, Akt can 
directly phosphorylate another cyclin-dependent kinase inhibitor, p21cip1/Waf1, causing its 
cytoplasmic accumulation and preventing its access to nuclear cyclin-Cdk targets42. Akt 
can also regulate G1/S cell cycle progression through inhibition of FoxO transcriptional 
factors. In fact, FoxO factors once in the nucleus, upregulate expression of three target 
genes which lead to G1/S arrest, p27
Kip1, p21Waf/Cip1 and the retinoblastoma family member 
p13024. Akt-dependent phosphorylation of these transcription factors leads to their nuclear 
exclusion and thus inhibition of FoxO factor-mediated gene expression. Moreover, FoxO 
factors can also promote cell cycle arrest by repressing the expression of cyclin D1 and 
D2, two positive cell cycle regulators45. It has also been reported that Akt plays a role in 
G2/M phase transition and its constitutive activation may lead to a defect in DNA damage 
checkpoint control. Gadd45a gene (Growth arrest and DNA damage 45a) is transactivated 
by FoxO3a. Thus, Akt would lead to FoxO3a phosphorylation and sequestration in the 
cytoplasm, thereby reducing Gadd45a expression46. Chk1 is also one of the candidates 
regulated by Akt pathway and involved in regulation of G2/M transition. Akt can 
phosphorylate Chk1 at Ser280 causing its inactivation that impair Chk1 mediated Cdc25C 
phosphorylation. Cdc25C is a phosphatase that positively regulates Cdc2, the cyclin-
dependent kinase 1 which is essential for G1/S and G2/M phase transitions of eukaryotic 
cell cycle. Following DNA damage, Chk1 phosphorylates Cdc25C leading to inhibition of 
Cdc2. Thus, Akt-mediated Chk1 inhibition could lead to resistance to DNA damage 
mediated G2/M arrest
42. 
 
Cell metabolism regulation. Activated Akt protein modulates the function of numerous 
substrates related to the regulation of cell proliferation, such as GSK3β, membrane 
translocation of the glucose transporter (GLUT4), mTOR and TSC2. Akt-mediated 
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activation of mTOR is important in stimulating cell proliferation, as mTOR acts as a 
checkpoint sensor indicating to cells that there are sufficient nutrients available to proceed 
through the cell cycle. mTOR regulates translation by phosphorylating components of the 
protein synthesis machinery, including S6K1 (which can also be directly activated by 
PDK1) and 4E-BP1: the first phosphorylates the 40s ribosomal protein, S6, leading to 
active translation of mRNAs, the latter induces release of the translation initiation factor 
eIF4E, allowing eIF4E to participate in assembly of a translational initiation complex24. 
mTOR favors the production of key molecules such as c-Myc, cyclin D1 and ribosomal 
proteins. By controlling protein synthesis, S6K1 and 4E-BP1 also regulate cell growth and 
hypertrophy. The TSC1/TSC2 complex opposes these effects by inhibiting S6K1 and 
activating 4E-BP1 to sequester eIF4E47. Akt inhibits TSC2 function through direct 
phosphorylation. TSC2 is a GTPase-activating protein (GAP) that functions to inactivate 
the small G protein Rheb (Ras homolog enriched in brain). TSC2 phosphorylation by Akt 
represses GAP activity of the TSC1/TSC2 complex, allowing Rheb to accumulate in a 
GTP-bound state24. Rheb-GTP then activates the protein kinase activity of mTOR when 
associated in the mTORC1 complex, and so this pathway is controlled by complicated 
interactions and feedback loops. For example, the TSC/Rheb/mTOR/S6K1 cascade 
regulates IRS1/2, which comprises an important feedback loop. In addition, the PI3K/Akt 
pathway interacts with molecular mechanisms controlling cellular energy control and 
glucose metabolism. LKB1-mediated activation of AMP-activated protein kinase (AMPK), 
an evolutionarily conserved sensor of the cellular ATP/ADP ratio, leads to inhibition of 
mTOR through TSC2 in response to energy depletion, thereby allowing energy 
conservation48. Another Akt substrate important for metabolic function is GSK3β, which 
phosphorylates and inactivates glycogen synthase in response to insulin stimulation. 
When phosphorylated by Akt on Ser9, GSK3β is downregulated49. Interestingly, GSK3β 
has been implicated in the signaling pathway elicited by Wnt, a ligand for transmembrane 
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receptor frizzled. The β-catenin protein is at the core of the canonical Wnt signaling 
pathway. Wnt stimulation leads to β-catenin accumulation, nuclear translocation and 
interaction with transcription factors to regulate genes important for development and 
proliferation, including FGF20, c-Myc, cyclin D1, DKK1,WISP1 and Glucagon (GCG)50-51. 
Phosphorylation of β-catenin by GSK3β on key N-terminal residues targets it for 
ubiquitination and breakdown in the proteasome. Therefore, Akt inhibition of GSK3β 
stimulates the transcription of such target genes. PI3K signaling also controls 
angiogenesis, growth, proliferation, senescence and other processes through mechanisms 
including vascular endothelial growth factor (VEGF) transcriptional activation and induced 
hypoxia inducible factor-1α (HIF1α) expression. The von Hippel Lindau (vHL) tumour-
suppressor protein, through its oxygen-dependent polyubiquitylation of HIF1α leading to 
HIF1α degradation, has a central role in the mammalian oxygen-sensing pathway by 
opposing the effects of the PI3K pathway52. 
 
1.3. Roles of class I PI3K signaling in T-lymphocytes 
Acquisition of a complete peripheral T cell repertoire requires that T cell progenitors 
undergo a series of tightly regulated developmental events that depend on integration of 
signaling cascades downstream of the pre-T cell receptor (TCR) and then the mature 
TCR. The first step in T cell development is the emigration of early thymic progenitors 
(ETPs) from the bone marrow to the thymus. ETPs then transit through four stages as 
CD4/CD8 double negative (DN) cells (DN1–4) before upregulating CD8 and CD4 to 
become double positive (DP) thymocytes. Emergence of mature T cells requires that 
developing thymocytes pass through several pre-TCR/TCR-dependent selection events: 
the first at the DN3 stage and then two others at the DP stage. DN3 thymocytes test the 
newly created pre-TCRβ chain for its ability to be functionally expressed during a process 
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known as β-selection, while DP cells test the reactivity of the mature TCR for 
selfpeptide/MHC during positive and negative selection53. 
The PI3K signaling regulates many steps in the development, activation and differentiation 
of T-cells. p110δ and p110γ are widely involved in thymocyte development, and 
differentiation, especially during β-selection and transition between immature DP and 
mature SP thymocytes54-55 and several genetic approaches have been taken to investigate 
the functional role of PI3K signaling during T-cell development, maturation and function. 
Indeed, the catalytic and regulatory subunits of class I PI3K exhibit complex patterns of 
redundant expression and it has been difficult to use genetically altered mice with single 
PI3K mutations to unravel the complete role for this signaling pathway in early thymocyte 
development or subsequent mature T cell function. 
PI3K activation, which occurs within seconds of T-cell activation, is essential during the 
early phases for T-cell proliferation. DN3 cell survival requires that signals delivered by 
multiple receptors, including Notch, the receptor for interleukin-7 (IL-7), and the pre-TCR, 
be appropriately integrated, and one pathway common to all three receptors is the PI3K 
signal transduction cascade. With regard to the PI3K regulatory subunits, it has been 
observed a redundancy in their function, as lack of p85α and/or p85β subunits exerted 
limited effects53. Although loss of function of the catalytic subunit p110δ had no 
measurable effect on T cell development, absence of p110γ resulted in decreased 
numbers of DP cells and a corresponding decrease in thymic cellularity. However, p110α 
and p110β seem to compensate the absence of p110δ expression56. Moreover, mice 
deficient in both catalytic subunits, p110δ and p110γ, have small thymi due to a 
combination of increased apoptosis and decreased proliferation at the β-selection 
checkpoint and DP stages53. Further studies demonstrated the predominant role, during 
the β-selection checkpoint, of PDK1 to sustain proliferation and of Akt to maintain survival 
and cellular metabolism for this continued division53. Finally, genetic and pharmacological 
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experiments have shown that PI3K activation also regulates many steps in the activation 
and differentiation of T-cells55.  
 
1.4. T-cell acute lymphoblastic leukemia (T-ALL) 
T-cell acute lymphoblastic leukemia is a malignant disorder of T-cell lymphoid progenitor 
cells that affects 15% of children and 25% of adults ALL57, and is characterized by 
cytogenetic and molecular alterations that contribute to the acquisition of the transformed 
leukemic phenotype (Figure 5). Clinically, T-ALL patients show diffuse infiltration of the 
bone marrow by immature T cell lymphoblasts, high white blood cell counts, mediastinal 
masses with pleural effusions, and frequent infiltration of the central nervous system at 
diagnosis58. In T-ALL, recurrent chromosomal rearrangements together with novel 
identified genetic alterations led to the aberrant expression of T-cell oncogenes that define 
different leukemogenic pathways associated with outcome. Furthermore, recent genomic 
profile and high-throughput sequencing studies have identified mutations affecting novel 
recurring targets. 
 
1.4.1. Common T-ALL cytogenetic alteration 
Structural chromosomal aberrations are identified in approximately 50% of T-ALL59 and 
frequently involve the juxtaposition of strong promoter and enhancer elements from T-cell 
receptor (TCR) genes (both TCRαδ at 14q11 and TCRβ at 7q34)60 with transcription 
factors genes as consequence of an illegitimate event during V(D)J recombination in 
normal T-cell development. This lead to the aberrant expression of these fusion partners 
resulting in thymocyte differentiation block at various stages of maturation.  
The basic helix-loop-helix (bHLH) family of transcription factors is characterized by a basic 
domain that mediates DNA binding, and a HLH motif that mediates homo and 
heterodimeric complex formation. TAL1 (1p32), LYL1 (19p13), TAL2 (9q32) and BHLH1 
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(21q22) are members of class II bHLH not expressed in normal thymus. TAL1 results 
ectopically expressed in T-ALL as consequence of t(1;14)(p32;q11)61 (3% in childhood T-
ALL) and more frequently as a consequence of the intrachromosomal deletion resulting in  
SIL-TAL1 fusion gene, while LYL1, TAL2 and BHLH1 are upregulated in the rare 
translocations t(7;19)(q34;p13)62, t(7;9)(q34;q32)63 and t(14;21)(q11;q22)64, respectively. 
Their aberrant expression may contribute to leukemia through the formation of 
heterodimers with class I bHLH members that regulate T-cell specific genes, with 
consequent differentiation and proliferation impairment. LIM domain only genes, LMO1 
(11p15) and LMO2 (11p13), are involved in t(11;14)(p15;q11)65 and t(11;14)(p13;q11)66 
with TCRαδ loci and in translocations with TCRβ60.  LMO proteins function during the early 
stages of hematopoiesis by associating with other proteins, including TAL1 and other 
bHLH components67, and their abnormal expression associate with deregulation of LYL1 
and TAL1, even in absence of specific  translocations68. The homeobox (HOX) genes are 
a highly conserved family of transcription factors that play an important role in 
morphogenesis during embryonic development and in normal hemopoiesis69. The 
inv(7)(p15q34) and t(7;7)(p15;q34) bring the TCRB regulatory elements in the vicinity of 
the HOXA genes cluster disrupting the normal regulatory elements of the cluster with 
subsequent upregulation, especially of HOXA9, HOXA10 and HOXA1170-71. TLX1 
(HOX11) is expressed at high level  in more than 30% of adult T-ALL as consequence of 
t(10;14)(q24;q11) and t(7;10)(q34;q24)72, while TLX3 (HOX11L2) is involved in 
t(5;14)(q35;q32) with the fusion partner BCL11B in about 20% children and 4% adults73. 
Additional genes rarely involved in TCR loci rearrangements are LCK74, CCND275 and 
IRS476. 
Furthermore, gene expression profiling studies have identified overexpression of these 
genes with a higher frequency compared with chromosomal rearrangements. Resulting 
signatures enable to classify T-ALL into major subgroups that are indicative of leukemic  
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arrest at specific stages of normal thymocyte development (HOX11+ early cortical 
thymocytes; LYL1+ early pro-T  thymocytes; TAL1+ late cortical thymocytes) and have 
clinical relevance, because are associated with a favorable or worse prognosis68. 
Moreover these results suggest that additional genetic lesions are involved in aberrant 
expression of these transcription factors. 
Additional genetic abnormalities in T-ALL include translocations that generate fusion 
transcripts encoding new chimeric proteins with oncogenic properties. The MLL gene 
(11q23) rearranges with multiple partners in both myeloid and lymphoid malignancies and 
is generally associated with a worse prognosis. In T-ALL overall MLL fusions represent 
about 8% and preferential partners are AF4 t(4;11)(q21;q23) and ENL t(11;19)(q23;p13.3), 
with the last one linked with a favorable outcome77. The t(10;11)(p13;q14) encoding 
CALM-AF10 fusion oncogene is found in about 10% of T-ALL, both in children and adults, 
despite it is often cryptic and requires molecular characterization78. Content in AF10 and 
prognostic significance appear to depend on stage of maturation arrest. The cryptic 
deletion del (9)(q34.11q34.13) results in the SET-NUP214 fusion product, which 
transcriptionally activate specific members of the HOXA cluster maybe contributing to T-
ALL pathogenesis by the inhibition of T-cell maturation79. The ABL1 cytoplasmic tyrosine 
kinase plays a role in T-cell signaling, leading to the induction of IL-2 production and 
proliferation following TCR activation80. ABL1 fusion genes can be identified in about 8% of 
T-ALL. EML1-ABL1 fusion due to a cryptic t(9;14)(q34;q32), BCR-ABL1 t(9;22)(q34;q11),  
and ETV6-ABL1 t(9;12)(q34;p13) are seldom reported chimeric genes in T-ALL, although 
they are frequent in other hematologic malignancies. In contrast, the most frequent and 
strictly associated with T-ALL is the NUP214-ABL1 fusion identified in 6% of cases, in both 
children and adults. However, its prognostic relevance is unclear81. The Janus kinase-
signal transducer (JAK) family are protein kinases that play an important role in promoting 
cell proliferation, differentiation, and survival in hematopoietic precursors. JAK2 is 
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constitutively activated in the rare t(9;12)(p24;p13) encoding the ETV6-JAK2 fusion 
oncoprotein, while JAK1  is  mutated widely mutated in adult T-ALL (18%) and less in 
children (3%), and associates with a poor response to therapy82. Finally, a recent study 
identified a novel fusion partner of ETV6 in one T-ALL patient, harboring ETV6-ARNT 
t(1;12)(q21;p13)83. 
 
1.4.2. Aberrant signaling in T-ALL 
NOCTH1 role in leukemogenesis was initially identified in the rare chromosomal 
translocation t(7;9)(q34;q34.3), that fuses the intracellular form of NOTCH1 to the TCRβ 
and leads to the expression of TAN1, a truncated and constitutively activated form of 
NOTCH184. Subsequently, activating  or loss of function mutations has been identified in 
more than 50% of T-ALL cases, representing the most common alteration in T-ALL85. After 
a protease cleavage mediated by γ-secretase, intracellular and active part of NOTCH1 
(ICN) translocates to the nucleus where it regulates many downstream targets including 
HES1, DTX1, PTCRA, NOTCH3, PTEN and MYC86. NOTCH1 activating mutations seem 
to correlate with a good prognosis in pediatric T-ALL87. Other components of this pathway 
are mutated in T-ALL, as FBXW788, a NOTCH1 proteasome-degradation mediator  whose 
mutations lead to ICN activation, or PTEN89, a NOCTH1 target and negative regulator of 
PI3K/Akt signaling pathway whose mutations lead to uncontrolled proliferation of T-cells. 
Other mutated genes in T-ALL are NRAS90, the negative regulator of the RAS pathway 
NF1 that is inactivated because of deletions or mutations91, and rarely FLT392-93 and 
PTPN294, that are affected by activating mutations and focal deletions, respectively. All 
these genes play crucial roles as regulators and alterations in their function may affect 
critically different signal transduction pathways.  
Another important pathway frequently deregulated in T-ALL is PI3K/Akt, as discussed 
below.  
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1.4.3. Novel molecular alterations identified in T-ALL 
The introduction of high resolution microarray technologies has improved the identification 
of novel aberrations that can contribute to the onset or development of leukemia. The 
recurrent genetic alteration, predominantly a heterozygous frameshift mutation, in the 
tumor suppressors WT1 has been identified in more than 10% of both pediatric and adult 
T-ALL and is associated with aberrant rearrangements of the oncogenic TLX1, TLX3, and 
HOXA transcription factor oncogenes95. LEF1, a member of the LEF/TCF family of DNA-
binding transcription factors, which interacts with nuclear β-catenin in the WNT signaling 
pathway, is inactivated  in 15% of childhood T-ALL and correlates with increased 
expression of MYC and MYC targets96. Deletion of 9p21.2 is a frequent event in T-ALL, 
being present in more than 70% of patients97.  Recent genomic profiling studies confirmed 
this observation, indicating that loss of the tumor suppressor genes CDKN2A/B and 
CDKN1B is a common and early event in leukemogenesis98-100. Other lesions identified in 
T-ALL are copy number alterations that affected the early lymphoid regulators IKZF1, 
IKZF2, and LEF1100. TGFβ is involved in proliferation of T-cell and its tumor suppressor 
pathway resulted inhibited in children T-ALL, through the loss of the intermediate Smad3.  
In recent years application of the novel whole genome scale technologies increased the 
knowledge about the genomic abnormalities which might sustain the onset/development of 
T-ALL, or which might contribute to the aggressiveness of the disease101. Despite that, T-
ALL pathogenesis is still unclear and no effective targeted therapies exist. Because T-ALL 
is an extremely heterogeneous disease, application of next generation sequencing (NGS) 
is further improving its characterization with novel notions translatable to clinical practice.  
Through the X-chromosome DNA capture followed by NGS, Ferrando et al102. identified a 
new X-linked tumor suppressor gene, PHF6 (PHD finger protein 6 on Xq26.3) with a 
proposed role in controlling gene expression, which inactivation is already associated with 
Borjeson-Forssman-Lehmann syndrome (BFLS, MIM301900). In T-ALL, mutational loss of 
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PHF6 is a somatically acquired leukemia-associated genetic events, mainly due to 
widespread nonsense and frameshift mutations, and to a lower extent to missense 
mutations, which impair gene expression or protein function. PHF6 mutations seem to be 
restricted to T-lineage ALL, are more frequent in males than females103 and prevail in 
adults compared to pediatric patients. Moreover, PHF6 mutations resulted associated with 
the aberrant expression of TLX1 and TLX368 and with mutations of NOTCH1, JAK1 and 
rearrangement of SET-NUP214104. However, the knowledge on PHF6 role in 
leukemogenesis is extremely limited and its clinical significance is still unclear102. The 
recently identified early T cell precursor leukemia (ETP ALL) is a novel subtype of T-ALL 
which comprises up to 15% of T-ALL and confers a poor prognosis105. ETP ALL is 
characterized by a peculiar immunophenotype pattern (absence of CD1a and CD8 
expression, weak CD5 expression, and expression of one or more myeloid- or stem cell-
associated markers such as CD13, CD33, CD34 and CD117). This pattern is similar to 
that of murine early T-cell precursor106 the thymic progenitors that have lost B-cell potential 
but still retain myeloid potential107. An extensive study of pediatric ETP ALL based on 
whole genome sequencing (WGS), transcriptome sequencing (mRNA-seq) and whole-
exome sequencing (WES), has been conducted to define common genetic 
abnormalities108. Although  ETP ALL appeared as a uniform immunophenotypic entity, no 
common alteration has been found. Overall, WGS analysis of 12 ETP ALL followed by a 
validation analysis in a recurrence cohort of 52 ETP ALL and 42 non-ETP ALL, confirmed 
a high degree of genetic instability105 which induces both structural rearrangements and 
sequence mutations. Interestingly, among the genes involved in translocations, the 
authors identified ETV6, a transcription factor frequently altered in leukemia which is 
deleted or mutated in a large proportion of ETP ALL compared to non-ETP ALL (33% vs 
10%)108. In addition to genes commonly mutated in T-ALL, pediatric ETP ALL sequence 
mutations/indels prevalently targeted cytokine receptor and RAS signaling pathway (e.g. 
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BRAF, FLT3, IGFR1, JAK1, JAK3, KRAS, NRAS ad IL7R); genes involved in 
hematopoietic development (e.g RUNX1, IKZF1, ETV6, GATA3 and EP300); components 
of the polycomb repressor complex 2 (PRC2) which contributes to histone modifications 
(e.g EED, EZH2 and SUZ12)108. In all the cases the percentage of mutated ETP ALL were 
extremely higher compared to non-ETP ALL. Novel recurrent somatic mutations have 
been found in DNM2, ECT2L and RELN, with unknown functions in normal lymphoid or 
leukemic development108. In adult ETP ALL109, WES analysis confirmed the presence of 
mutations in several genes, including the novel DNM2, and revealed the involvement of 
epigenetic regulators, in particular MLL2, DNMT3A, and with a lower rate PRC2. Of note, 
DNMT3A mutations are highly recurrent in patients with de novo acute myeloid leukemia 
(AML)110, highlighting the early maturational stage of ETP ALL, and encouraging the 
application of therapies used for AML treatment. RUNX1 and DNMT3A mutations have 
also been identified in adult T-ALL, were resulted associated with shorter overall 
survival111. The mutational spectrum of typical T-ALL has been recently analyzed with 
WES in a large cohort of more than 60 adult and pediatric samples112. Through an 
accurate filtering approach, novel mutations have been detected in a set of candidate 
driver genes, including CNOT3, proposed to act as a tumor suppressor, and RPL5 and 
RPL10, two genes encoding ribosomal proteins. Moreover, this study pointed out the clear 
correlation between the increase in patients age and mutation number, and the differences 
in mutation distribution between adult and pediatric T-ALL, with CNOT3 mutations mainly 
present in adults, whereas RPL10 mutations almost exclusively found in children. 
Nowadays, only one study has been conducted to compare matched diagnosis, remission 
and relapse samples, by means of WES113. The most remarkable finding of this study was 
the identification of relapse-associated mutations in NT5C2 (5'-nucleotidase, cytosolic II), 
involved in cellular purine metabolism. NT5C2 mutations prevail in relapsed T-ALL 
compared to relapsed B-ALL (19% vs 3%, respectively). These mutations affect the 
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nucleotidase activity of NT5C2 compared to wild-type, and confer resistance to the 
nucleoside analogs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) commonly used in 
ALL treatment, as assessed in in vitro cellular model. 
The sensitivity and accuracy of the high-throughput sequencing (HTS) have been 
translated into clinical practice through a targeted sequencing of TCR gene loci (TCRB 
and TCRG) by Wu et al., who identified in pre-treatment samples the recombined TCR 
gene sequences representing the patient’s clonal neoplastic T lymphoblasts, and 
evaluated minimal residual disease (MRD) in paired post-treatment T-ALL patients114. The 
importance to assess MRD in order to predict clinical outcomes of patients is broadly 
recognized115. Compared to conventional multiparametric flow cytometry (mpFC) 
approach, there were no cases in which MRD was detected by mpFC but not by HTS. 
Moreover, HST enabled detection of the clonal TCR rearrangement in post-treatment 
samples where mpFC failed to do it, highlighting the potential of this technology to improve 
clinical diagnosis, patients’ stratification and subsequent MRD monitoring with lower 
detection thresholds.  
NGS approach has also been successfully used in T-ALL murine116 and cellular model117. 
Exon capture sequencing in a murine model for heritable T-ALL, called Spontaneous 
dominant leukemia (Sdl), detected a spontaneously acquired dominant mutation in Mcm4 
(Mcm4D573H), which encodes for a protein essential for the initiation of eukaryotic genome 
replication. Mcm4D573H is likely the causative tumor genetic lesion in Sdl, although if the 
role of MCM proteins is still unclear in human cancers116. Whole transcriptome deep 
sequencing of Jurkat cell line identified T-ALL-R-LncR1 as a novel long non-coding RNAs 
associated to T-ALL117. LncRNAs are transcribed RNA molecules but do not encode 
proteins and have an emerging role in cancer progression118. T-ALL-R-LncR1 were not 
detected in normal tissue specimens, while its expression was confirmed in tumor tissues 
and T-ALL patients samples. Moreover, knockdown of T-ALL-R-LncR1 predisposed T-ALL 
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Jurkat cells to undergo Par-4 (the proapoptotic factor prostate apoptosis response protein-
4)-induced apoptosis. Although if these results obtained in murine or cellular models 
require further investigations in human T-ALL, they provided novel findings suitable to 
identify innovative targeted therapies.  
 
 
 
Figure 5: Estimated frequency of specific genotypes in childhood ALL. The pie chart includes comprises both B-lineage and T-
lineage ALLs, to illustrate the relative frequency of each. The genetic lesions that are commonly associated with T-ALL are 
indicated in gold and those commonly associated with B-ALL in blue. The darker gold or blue color indicates those subtypes 
generally associated with poor prognosis
119
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1.5. Activation of class I PI3K signaling in T-ALL 
PI3K/Akt pathway is constitutively activated in more than 80% of T-ALL cases120. One 
mechanism responsible for PI3K activation is the presence of growth factors in the 
leukemia milieu that signal through cytokine receptors. Moreover,  T-ALL cell lines present 
constitutively phosphorylated forms of Akt independently of external growth factors. In 
addition, NF-κB, a downstream target of PI3K/Akt, is constitutively activated in some 
primary T-ALL samples121. Nevertheless, conversely to solid tumors122, no activating 
mutations of PI3K and/or Akt have been described in T-ALL. It has been suggested that 
PI3K/Akt pathway over-activation results as a consequence of PTEN gene mutations89. 
However, whereas lack of PTEN protein is frequent in T-ALL cell lines, PTEN deletions as 
well as PTEN inactivating mutations predicted to cause protein truncation are low 
frequency events in T-ALL samples. Moreover, PTEN mutations resulting in protein 
truncation have been identified more frequently in T-ALL cell lines established from 
relapsed patients than in diagnostic clinical specimens, which suggests that PTEN deletion 
is a late event in human T-ALL123. In contrast, studies using mouse models have shown 
that PTEN deregulation is important at early stages of leukemogenesis. In these models, 
PTEN expression was shown to be essential to maintain the hematopoietic stem cell pool 
and to prevent leukemia development124-125. According to these observations, several 
studies have demonstrated that non-deletional inactivation of PTEN is a major contributor 
to hyperactivation of PI3K/Akt in primary T-ALL samples. PTEN posttranslational 
inactivation includes CK2-mediated phosphorylation and ROS-dependent oxidation of 
PTEN120. CK2 and PTEN can physically interact, and CK2-mediated phosphorylation of 
PTEN affects its activity and stabilizes the protein by preventing proteasome-mediated 
degradation. CK2 is overexpressed and hyperactivated in primary T-ALL cells and CK2-
mediated phosphorylation of PTEN at Ser380 stabilizes PTEN expression and inhibits its 
activity, ultimately leading to PI3K/Akt pathway constitutive activation120. Moreover, high 
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ROS levels determine constitutive oxidation and inactivation of PTEN in T-ALL cells120. 
Further studies demonstrated a crosstalk between PI3K/Akt signaling pathway and ROS 
that is essential for IL-7-mediated T-ALL cell survival, as IL-7-mediated activation of PI3K 
pathway upregulates ROS through the upregulation of the glucose transporter Glut1 in T-
ALL cells126. As mentioned above, gain-of-function mutations in NOTCH1 are common in 
T-ALL. It exists a complex interplay between PI3K-Akt upregulation, loss of PTEN function 
and NOTCH1 mutations that might be crucial for risk assessment, prediction of response 
and identification of effective targeted therapies in T-ALL patients127. Indeed, NOTCH1 
regulates the expression of PTEN and the activity of the PI3K/Akt signaling pathway in 
normal and leukemic T cells. NOTCH1 mediates the transcriptional downregulation of 
PTEN through HES1, a transcription factor directly controlled by NOTCH189. Therefore, 
activation of NOTCH1 in T-ALL also mediate the upregulation of the PI3K/Akt. This finding 
provide the basis for the design of therapeutic approach for T-ALL based on combined 
inhibition of both NOTCH1 and PI3K. 
 
1.6. Therapeutic strategies to target PI3K/Akt/mTOR  pathway 
Class I PI3K signaling is activated in different human cancers via several different 
mechanisms. In solid tumors, increased PI3K signaling is often due to direct mutational 
activation or amplification of genes encoding key components of the PI3K pathway such 
as PIK3CA, PIK3CB, PIK3R1, AKT1 and PDK14. PTEN is frequently mutated or deleted in 
solid tumors, as gastric, prostate or endometrial cancers, whereas it is frequently 
deregulated by posttranslational inactivation in T-ALL. PI3K also can be activated by 
genetic mutations and/or amplification of upstream RTKs, and possibly by mutationally 
activated Ras16. Moreover, in class I PI3Ks, the different isoforms of p110 and p85 
preferentially mediate specific signaling processes, as suggested by biochemical and gene 
knockout studies with, however, a degree of redundancy. Therefore, it might be necessary 
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to develop isoform-specific inhibitors to decrease toxicity or pan inhibitors to increase 
efficacy. The mechanism of PI3K activation in an individual cancer may suggest the most 
effective type of therapeutic to inhibit the pathway (Table 1 and Figure 6). 
 
Dual PI3K/mTOR Inhibitors. The catalytic domains of the p110 subunits and mTOR are 
structurally similar, because they all belong to the phosphatidylinositol kinase–related 
kinase family of kinases. Many chemical inhibitors under development inhibit both mTOR 
and the p110 catalytic subunits. These are termed dual PI3K/mTOR inhibitors. When 
compared with the other types of PI3K pathway inhibitors, dual PI3K/mTOR inhibitors have 
the possible advantage of inhibiting all PI3K catalytic isoforms, mTORC1 and mTORC2. 
Thus, they should effectively turn off this pathway completely and overcome feedback 
inhibition normally observed with mTORC1 inhibitors (e.g. rapamycin) that may limit their 
efficacy. However, it remains unknown if dual PI3K/mTOR inhibitors will be tolerable at 
doses that effectively inhibit all p110 isoforms and mTOR, or if their use will necessitate 
sacrificing complete inhibition of one or more of the potential targets. The pioneer 
PI3K/mTOR inhibitor is LY294002, which has been extensively used to explore the 
therapeutic potential of PI3K/mTOR inhibition in different cancer models, although it is 
unsuitable for patient use. Subsequently, other PI3K/mTOR inhibitors have entered clinical 
trials. Dual inhibitors being investigated in the clinical setting include BEZ235, SF1126, 
XL765 (SAR245409), PF-04691502, PF-05212384, GDC-0980, GSK2126458, and DS-
7423128. With the potential to block compensatory signaling or feedback loops, dual 
PI3K/mTOR inhibitors represent an interesting drug class. Preliminary data show that 
simultaneous inhibition of all PI3K isoforms, mTORC1, and mTORC2 is feasible in the 
clinical setting, although several adverse events have been reported128. Robust clinical 
trials are needed to determine whether dual PI3K/mTOR inhibitors have a significant 
therapeutic advantage.  
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Pan PI3K Inhibitors. The PI3K inhibitors can be divided into isoform-specific inhibitors or 
pan-PI3K inhibitors. Pan PI3K inhibitors target all class IA PI3K  isoforms (α, β, γ, δ). It has 
been hypothesized that inhibiting all 4 isoforms of class I PI3K may be advantageous over 
inhibiting specific isoforms. Some pre-clinical studies suggest that functional redundancy 
may lead to compensatory signaling after genetic or pharmacological inactivation of 
specific isoforms128. Pan PI3K inhibitors include wortmannin derivatives such as PX-886 or 
wortmannin prodrugs such as the self-activating viridians modified by dextran linker 
moieties16. Recently, novel pan PI3K inhibitors have been tested in both preclinical and 
clinical models. Pan PI3K inhibitors such as BKM120, XL147 (SAR245408), BAY 80-6946, 
PX-866, and GDC-0941 have demonstrated potent anticancer activity. BKM120 is a 
dimorpholinopyrimidine derivative that blocks Akt phosphorylation and inhibits tumor 
growth. The pan inhibitor BKM120 has been evaluated in both preclinical leukemic 
models129 and phase I clinical trials for patients with solid tumors130-132, demonstrating its 
efficacy as a single agent or in combination with other therapies. BKM120 is at present 
extensively studied in phases I-III clinical trials which prevalently involve patients with 
advanced solid tumors. Moreover, BK120 efficacy is being evaluated in hematologic 
malignancies. A phase I study enrolling adults with advanced leukemias (NCT01396499); 
two studies enrolling Refractory Non-Hodgkin Lymphoma (NCT01719250, NCT01693614); 
a phase I study enrolling relapsed or refractory indolent B-Cell Lymphoma patients 
(NCT02049541). ZSTK-474 is another pan PI3K inhibitor which has been tested in 
preclinical settings133-135 and is currently in clinical development. Overall, pan PI3K 
inhibitors have shown encouraging anticancer activity as single agents or in combination 
with other agents, and results from ongoing trials are eagerly awaited. Further 
investigation is needed to determine whether complete inhibition of all isoforms is 
necessary or the reliance of different tumors on PI3K isoforms will only require selective 
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isoform inhibitors, and whether the doses required for total target inhibition will be tolerable 
in patients. 
 
Isoform-specific PI3K inhibitors. Selective PI3K inhibitors may have benefit in tumors in 
which a particular isoform is predominantly expressed or more critical for survival. For 
example, PI3Kα is expressed and frequently mutated in many tumor types; p110β has 
been suggested to control basal PtdIns(3,4,5)P3 production and drive prostate tumour 
formation when PTEN is inactivated136; p110δ and p110γ are mainly expressed in 
hematopoietic cells. Blocking the activity of specific isoforms that are crucial for survival 
could theoretically provide complete target inhibition at tolerable doses and maximize the 
toxic effects of this drug class. PI3Kα-specific inhibitors are expected to be highly effective 
in tumors harboring PIK3CA activating mutations and several drugs, as BYL719, INK1117, 
and GDC-0032 are being evaluated in patients with solid tumors. KIN-193 and 
GSK2636771 specifically target the p110β isoform, and the latter entered clinical trials for 
PTEN-deficient solid tumors128. Because of the important role of p110δ and p110γ 
isosforms in hematopoietic cells, dual PI3K inhibitors represent a possible strategy to treat 
blood malignancies. Accordingly, efficacy of IPI-145, that selectively inhibits p110δ and 
p110γ, is being evaluated in several clinical trials enrolling  ALL, CLL (Chronic 
Lymphocytic Leukemia) and Lymphoma patients128. Among the isoform specific PI3K 
inhibitors in development, idelalisib (CAL-101) which selectively inhibit p110δ, is the most 
studied in hematologic malignancies and is being evaluated in several phase III studies. 
Because of the important role of p110δ in B-cell, CAL-101 resulted high effective in CLL 
treatment137. 
 
Other strategies to inhibit PI3K signaling. As mentioned above, PI3K signaling pathway 
might be activated due to mutations that affect different components of the pathway as 
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well as alterations in upstream molecules. Therefore, beyond PI3K inhibition, other 
therapeutic strategies have been developed, including Akt and mTOR inhibition. Cancers 
with Akt1 mutations and Akt1 and Akt2 amplifications may be expected to be among the 
more sensitive to Akt inhibitors. However, this class of inhibitors will not block the non-Akt 
effectors of PI3K signaling and, paradoxically, could actually increase PI3K-dependent 
activation of those effectors via loss of negative feedbacks. This is especially important in 
light of the findings that the PDK1 substrate SGK3, and not Akt, may play a more 
prominent role in promoting PI3K-dependent viability in some cancers harboring PIK3CA 
mutations16. Whereas rapamycin specifically inhibits mTOR only in mTORC1, ATP-
competitive mTOR inhibitors target the kinase domain of mTOR to impede the activity of 
both mTORC1 and mTORC2. Inhibiting mTORC2 would provide the theoretical advantage 
of blocking Akt activation16. 
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Figure 6: Schematic representation of class I PI3K signal transduction pathway. Points of therapeutic inhibition are highlighted
138
. 
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Table 1: Sveral PI3K pathway inhibitors which are tested in clinical trials. Adapted from Weigelt and Downward
138
. 
Inhibitor name Target Clinical trial phase Cancer type 
PAN-CLASS I PI3K INHIBITORS 
BAY80-6946 Class I PI3K I Solid cancers 
ZSTK474 Class I PI3K I Solid cancers 
GSK1059615 Class I PI3K I Solid cancers 
BKM120 Class I PI3K I/II 
Solid cancers, hematological malignancies 
(leukemia) 
GDC-0941 Class I PI3K I/II 
Solid cancers, hematological malignancies 
(lymphoma) 
ISOFORM SPECIFIC PI3K INHIBITORS 
BYL719 p110α I Solid cancers 
GDC-0032 p110α I Solid cancers 
INK-1117 p110α I Solid cancers 
GSK2636771 p110β I/IIa Solid cancers 
IPI-145 p110γ/δ I Hematological malignancies 
AMG319 p110δ I Hematological malignancies 
CAL-101 p110δ I/II/III Hematological malignancies 
DUAL PI3K/mTOR INHIBITORS 
GDC-0980 PI3K/mTOR I 
Solid cancers, hematological malignancies 
(lymphoma) 
GSK2126458 PI3K/mTOR I Solid cancers 
BEZ235 PI3K/mTOR I/II Solid cancers 
BGT226 PI3K/mTOR I/II Solid cancers 
PF-05212384 PI3K/mTOR I/II Solid cancers 
XL765 PI3K/mTOR I/II Solid cancers 
mTOR INHIBITORS 
INK-128 mTOR (kinase) I 
Solid cancers, hematological malignancies 
(myeloma) 
OSI-027 mTOR (kinase) I 
Solid cancers, hematological malignancies 
(lymphoma) 
CC-223 mTOR (kinase) I/II Solid cancers, hematological malignancies 
Everolimus mTOR (allosteric) I/II/III Solid cancers, hematological malignancies 
Temsirolimus mTOR (allosteric) I/II Solid cancers, hematological malignancies 
AKT INHIBITORS 
GDC-0068 Akt I/II Solid cancers 
GSK2110183 Akt I/II Solid cancers, hematological malignancies 
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2. AIMS 
  
47 
 
Despite improvements in cure rates due to the introduction of intensified chemotherapy in 
modern protocols, the outcome of T-ALL patients with chemoresistant or relapsed 
leukemia is still poor58. T-ALL requires aggressive chemotherapy with well-known long-
term side effects. To minimize and ultimately overcome the detrimental effects of current 
therapeutic regimens, it is essential to identify novel molecular targets in T-ALL in order to 
develop and test selective inhibitors of such targets58. In T-ALL, PI3K/Akt pathway 
activation is a common event that results from alterations such as phosphorylation, 
oxidation, and gene deletion/mutation, which directly affect PTEN function89,120,126 or affect 
upstream regulators of the pathway139. Therefore, PI3K is an attractive target to efficiently 
treat T-ALL140-141.  
The overall aim of this research has been to investigate the therapeutic potential of PI3K 
signaling inhibition in T-ALL. Studies were conducted in order to: 
 
I. Investigate the efficacy of the pan inhibitor BKM120 both in vitro and in vivo in T-ALL 
models- 
II. Define the better therapeutic approach to treat T-ALL, by comparing pan and isoform-
specific PI3K inhibition. 
 
BKM120 is a potent and highly selective pan-class I PI3K inhibitor which belongs to the 
2,6-dimorpholino pyrimidine derivatives. It inhibits wild type and mutant PI3K p110α, β, δ, 
and γ isoforms but is inactive against class III PI3K and other kinases142. BKM120 has also 
been shown to exert a strong antiproliferative effect and to induce apoptosis in several 
cancer cell lines and mouse models of solid cancers by specifically inhibiting the biologic 
function of the PI3K downstream target Akt143-145. During this research period, BKM120 
efficacy has been assessed for the first time in T-ALL demonstrating the potential of 
BKM120 in T-ALL treatment. 
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However, which class of agents among isoform-specific or pan inhibitors can achieve the 
greater efficacy is still an open question, as recent studies reported opposite results about 
the usefulness of dual p110γ and p110δ146 or the importance to blockade all class I PI3K 
isoforms to efficiently inhibit cell proliferation in T-ALL147. However, both these studies 
considered only PTEN-null T-ALL, whereas deletion of PTEN are rare events in T-ALL. 
Therefore, further analyses have been conducted to investigate the effects of PI3K 
inhibition in both a PTEN deleted and non-deleted cellular context, in order to elucidate the 
mechanisms responsible for the proliferative impairment of T-ALL.  
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3. MATHERIAL AND METHODS 
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3.1. Compound and reagents 
PI3K inhibitors BKM-120, PIK-90, ZSTK-474, A-66, TGX-221, AS-605240, CAL-101 and 
IPI-145, the caspase inhibitor z-VAD and the autophagy inhibitors 3-methyladenine (3-
MA), Bafilomycin A1 (Baf A1) and E64D were from Selleck Chemicals (Houston TX, 
USA).The chemotherapeutic drugs doxorubicin and vincristine were from Sigma-Aldrich 
(St. Louis, MO, USA). Drugs were dissolved in DMSO at a final concentration of 10 mM for 
in vitro studies or as described below for in vivo administration, and stored at -80°C until 
use. The insulin-transferrin-sodium selenite (ITS) supplement was purchased from Sigma-
Aldrich. For western blotting analysis, the PI3K p110δ and β-Actin antibodies were from 
Santa Cruz Biotechnology (Heidelberg, Germany). All other primary and secondary 
antibodies were bought from Cell Signaling Technology (Danvers, MA, USA). RPMI 1640 
and MEM Alpha media, Hanks’ balanced salt solution (HBSS) and fetal bovine serum 
(FBS) were from Life Technologies Italia (Monza, Italy).  
 
3.2. Cell lines and primary samples 
Human T-ALL cell lines Jurkat, Loucy, RPMI-8402, BE-13, HPB-ALL, PF-382, P12-
ICHIKAWA, DND-41, MOLT-4, ALL-SIL, CCRF-CEM (CEM-S) and its resistant variant 
CEM-R (CEM-VBL100, drug-resistant cells overexpressing the ABCB1 drug transporter148) 
were grown in RPMI 1640 medium supplemented with 10-20% FBS, 100 U/ml penicillin 
and 100 μg/ml streptomycin (Sigma-Aldrich) at 37˚C in a humidified atmosphere of 5% 
CO2. DND-41 and MOLT-4 cells stably expressing luciferase and eGFP (DND-
41.Luc.GFP and MOLT-4.Luc.GFP cells) were generated as described elsewere149, grown 
in the same conditions and used for in vivo studies. MS-5 mouse stromal cells were grown 
in MEM Alpha medium supplemented with 10% FBS. Samples from T-ALL patients (n=6) 
were obtained with informed consent according to institutional guidelines, isolated using 
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Ficoll-Paque (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and grown in RPMI 
1640 medium supplemented with 20% FBS and ITS. 
 
3.3. Cell viability analysis and cell count 
To test the effects of PI3K inhibitors, T-ALL cell lines were cultured for 24 or 48 h in the 
presence of the vehicle (DMSO 0.1%) or increasing drug concentrations, and cell viability 
was determined using the MTT [3-(4,5-Dimethylthythiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] cell proliferation kit (Roche Diagnostic, Basel, Switzerland), according to 
manufacturer's instructions. Briefly, cells were plated in a 96-well plate (2.5 to 5x104 cells 
per well, 100 ml cell suspension per well) and cultured overnight in 10-20% serum to allow 
for exponential growth of cells. Cells were then treated with increasing concentrations of 
the drugs for the indicated times. At the end of the treatment, 10 µl 1X MTT labeling 
reagent was added to each well and incubated for another 4 h. The samples were 
solubilized with 100 µl of solubilization solution overnight at 37 °C. The optical density 
absorbance value of each well was read on a microplate reader (Bio-Rad) at 570 nm with 
a the reference wavelength at 690 nm. Every sample was performed in triplicate and in 
three independent experiments. The fraction of viable cells was calculated as follows: 
mean optical density value treated cells/mean optical density value control cells. 
For drug-combination experiments, a combination index (CI) number was calculated using 
the CalcuSyn software (Cambridge, UK) based on the Chou and Talalay method150. CIs 
are calculated with the formula Ca/Cxa x Cb/Cxb, where Cxa and Cxb are the 
concentrations of compound a and b alone, respectively, needed to achieve a given effect 
(x%) and Ca and Cb are the concentrations of compound a and b needed for the same 
effect (x%) when the drugs are combined. CI values between 0.1-0.9 define different 
grades of synergism, values between 0.9-1.1 are additive, whereas values >1.1 are 
antagonistic. Growth curves were generated by counting viable and non-viable cell 
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numbers by the Trypan blue dye exclusion method. Cells were seeded in 6-well plates, 
treated with the inhibitors at indicated concentrations or the vehicle alone (DMSO 0.1%) 
and counted at regular intervals up to 72 h. Doubling time was calculated with Roth V. 
2006 (http://www.doubling-time.com/compute.php). 
 
3.4. Flow cytometry analyses 
Apoptosis detection. Apoptosis was determined by the binding of Annexin V-FITC to 
phosphatidylserine exposed to the cell membrane using the Annexin V-FITC Apoptosis 
Detection Kit (eBiosciences) and according to the manufacturer’s instructions. A propidium 
iodide (PI) staining was also performed to simultaneously detect different populations of 
living, apoptotic and necrotic cells. Briefly, 1x106 cells per sample were collected by 
centrifugation, washed in phosphate buffered saline (PBS, pH 7.4), and incubated with 
Annexin V-FITC in binding buffer for 15 min. After that, cells were washed, resuspended in 
binging buffer, stained with PI and analyzed. 
Cell cycle analysis. Cell cycle analysis was performed using a PI/RNase A staining 
according to standard procedures. Cells were collected, washed with cold PBS and 
fixed/permeabilized with 70% ethanol at -20°C overnight. Subsequently, cells were 
washed in cold PBS, stained with PI (40 μg/ml) in the presence of RNase, and analyzed. 
At least 10,000 events/sample were recorded. 
Flow cytometric detection of p-Akt(Ser473) and p-S6RP(Ser235/236). Cells were 
collected by centrifugation, washed in PBS, fixed at 37°C for 10 min in PBS with 2% 
formaldehyde and left overnight at -20°C in methanol 90% for permeabilization. Cells were 
then washed in PBS supplemented with 4% FBS and incubated overnight with the primary 
antibody (Cell Signaling Technology) at 4°C.  Finally, after washing, cells were incubated 1 
hour with the appropriate secondary FITC-conjugated antibody and analyzed. 
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Flow Cytometry analysis of Ki-67 and PtdIns(3,4,5)P3. In order to evaluate effects on 
proliferation, Ki-67 antigen expression during the different phases of cell cycle was 
evaluated. After 72 h treatment, cells were permeabilized with methanol/acetic acid (3:1) 
and incubated with the Ki-67 primary antibody (Cell Signaling Technology). Afterwards, 
samples were stained for 1 h with a FITC-conjugated secondary antibody (Beckman 
Coulter, Miami, FL, USA) followed by  further 20 min incubation with PI. To detect 
PtdIns(3,4,5)P3 levels, control (DMSO 0.1%) and treated (6 h) cells were fixed in 4% 
paraformaldehyde for 15 min, permeabilized in 0.4% Triton X-100 for 10 min, washed in 
PSB 1X with 1% BSA and incubated over night at 4°C with the FITC-conjugated Anti-
PI(3,4,5)P3 antibody (Echelon Biosciences Inc., Salt Lake City, UT).  
All the analyses were performed on an FC500 flow cytometer (Beckman Coulter, Miami, 
FL, USA) with the appropriate software (CXP, Beckman Coulter). 
 
3.5. Western blot analysis 
Immunoblotting was performed by standard methods. Cells were lysed using the M-PER 
Mammalian Protein Extraction Reagent supplemented with the Protease and Phosphatase 
Inhibitor Cocktail (Thermo Fisher Scientific Inc., Rockford, IL, USA). Cells were plated in 
RPMI 1640 complete medium at an initial concentration of 2.5 to 5x105 cells per ml and 
incubated for 24 h before drug treatment. Cells were collected by centrifugation and 
washed in cold PBS. Cell pellets were then lysed in 100–200 µl of M-PER Mammalian 
Protein Extraction Reagent (Thermo Fisher Scientific Inc., Rockford, IL, USA) 
supplemented with Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific 
Inc.) and incubated on ice for 30 min. Cell debris were removed by centrifugation at 13000 
r.p.m. for 25 min at 4 °C in a microfuge. Protein supernatants were collected, heated to 95 
°C for 5 min, cooled on ice and were used for further analysis or stored at -80 °C. Equal 
amounts of protein samples (30 µg) were separated on sodium dodecylsulfate-
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polyacrylamide gel electrophoresis and electrotransferred onto nitrocellulose membranes. 
Membranes were briefly washed in PBS-0.1% Tween-20 (PBS-T) and nonspecific binding 
sites were blocked in 5% non-fat dry milk in PBS-T for 1 h at room temperature with gentle 
agitation. After PBS-T washes, membranes were incubated overnight at 4 °C with primary 
antibodies diluted according to the manufacturer’s instructions. Membranes were then 
incubated with horseradish peroxidase-conjugated secondary antibodies diluted 1:2000 in 
5% non-fat dry milk in PBS-T for 1 h at room temperature with gentle agitation. Proteins 
were detected using the Amersham ECL Prime Western Blotting Detection Reagent (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK), the ChemiDoc-It2 Imaging System and 
the VisionWorksLS Software for the analysis (UVP, LLC, Upland, CA). 
 
3.6. T-ALL cell co-culture with MS-5 mouse stromal cells 
Jurkat cells were seeded at 2.5 X 105/ml and, after an overnight incubation, cell 
suspension was transferred on the top of MS-5 mouse stromal cells (at ~70% confluence) 
and treated with BKM120. After 48 h, Jurkat cells were harvested, washed and incubated 
with a phycoerythrin (PE)-conjugated anti-CD45 antibody (Beckman Coulter, Brea, CA, 
USA) or with an irrelevant isotypic control antibody. After a 30 min incubation, cells were 
resuspended in binding buffer containing Annexin V-FITC and analyzed by flow cytometry 
after electronic gating on CD45+ leukemic cells. 
 
3.7. Flow cytometric detection of T-ALL side population (SP)  
Vybrant® DyeCycle (Life Technologies Corporation, Grand Island, NY, USA), a cell-
permeable DNA binding dye suitable for SP analysis on a violet laser flow cytometer, was 
employed for staining SP cells. Cells were suspended in HBSS containing 2% FBS and 2 
mM HEPES buffer and incubated for 90 minutes at 37°C with 10 μM Vybrant® DyeCycle 
in 5% CO2 atmosphere. To demonstrate staining specificity, control and treated cells were 
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pre-incubated with the multidrug transporter inhibitor Verapamil (Sigma-Aldrich) at a final 
concentration of 50 μM before dye addition. SP cells were co-stained with Annexin V-FITC 
to detect apoptosis. After DyeCycle incubation, cells were washed twice with RPMI 1640, 
containing FBS 2%, and 10 μL of cell pellet were resuspended in 5 μL of Annexin V-FITC 
(Actiplate-FITC kit, Tau Technology, Kattendijke, NL) and 485 μL of binding buffer, 
following the manufacturer's instructions. Cells were then maintained at 4°C for 20 min and 
analyzed on a Navios flow cytometer, equipped with a violet laser diode 405, and Kaluza 
software (Beckman Coulter). The flow cytometer filter set consisted of a 405 nm blue 
band-pass and a 675 nm red band-pass filter, for SP analysis. For Annexin V-FITC 
analysis, the 488 nm laser excitation was used (basic set). 
 
3.8. In vivo subcutaneous human T-ALL mouse models 
Mice were housed and bred in a specific pathogen-free animal facility, treated in 
accordance with the European Union guidelines and approval of the Institutional Ethical 
Committee of Instituto de Medicina Molecular, Lisbon, Portugal. Eight week old NOD/SCID 
mice were subcutaneously injected in both flanks with 10 x 106 DND-41.Luc.GFP or 
MOLT-4.Luc.GFP cells resuspended in 100L of PBS. At day 5, mice were injected with 
luciferin to assess tumor burden by whole-body bioluminescence imaging and were 
equally distributed in 2 groups to receive 40mg/Kg BKM120 dissolved in 10% N-Methyl-2-
pyrrolidone, 90% PEG 300 (po, daily) or vehicle control. Tumor growth was monitored 
twice weekly by bioluminescence and caliper measurements and mice were weighed 
frequently to determine treatment-induced toxicity. For bioluminescence imaging, mice 
were anaesthetized, intraperitoneally (i.p.) injected with 1.5mg luciferin/g, and scanned 
with an IVIS Lumina bioimaging device (Caliper Life Sciences, Hopkinton, MA, USA), after 
15 minutes, as described149. Total flux (photons per second) was calculated using Living 
Image software (Caliper Life Sciences). For caliper measurements tumor volume was 
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calculated using the formula: volume = length x width2 / 2, as described153. Mice were 
sacrificed at day 40 (DND-41.Luc.GFP cells) and day 50 (MOLT-4.Luc.GFP cells) after cell 
transfer. 
 
3.9. Gene expression analysis 
Total RNA was isolated either from control (DMSO 0.1%) and from 24 h ZSTK-474 treated 
cells using RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s 
instructions. RNA concentration was determined by measuring the absorbance at 260 nm; 
for all samples, the OD 260/OD 280 absorbance ratio was of at least 2.0. 3.5 µg of total 
RNA were reverse-transcribed into cDNA using the iScriptTM Advanced cDNA Syntesis Kit 
(Bio-rad, Hercules, CA, USA). Gene expression of specific autophagy markers was 
measured using the PrimePCRTM  Assay for real-time (Bio-rad). For each sample, cDNA 
was mixed with 2x SsoAdvancedTM universal supermix (25 ng cDNA/reaction) containing 
SYBR Green (Bio-rad) and aliquoted in equal volumes to each well of the real-time PCR 
arrays. The quantitative PCR reaction was performed using a 7300 Real-Time PCR 
system (Applied Biosystems, Foster City, CA, USA). The quantitative PCR thermal 
protocol consisted of 95°C for 2 minutes, followed by 40 cycles of 95° C for 5 seconds and 
60° C for 30 seconds. RLP0 was used as control gene and the relative gene expression 
among samples was calculated as 2-∆Ct154. These data were then subjected to hierarchical 
clustering using the Spearman’s rank correlation metric and the average-linkage method 
and heatmaps were generated using the data analysis tool TIGR Multiexperiment Viewer 
(http://www.tm4.org/)155. To examine the effects of pan PI3K inhibition in the different cell 
lines, gene expression of the treated cell lines was compared with that of  untreated 
control and fold change due to the treatment was expressed as 2-∆∆Ct154. A 2.0-fold change 
in gene expression was used as the cut-off threshold. 
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3.10. Statistical analysis 
Significant effects between treatment and control groups in the in vitro studies were 
analyzed using the Student’s unpaired t test and the Dunnett's test. In vivo differences in 
tumor development and survival were determined by two-way ANOVA and LogRank test, 
respectively. Differences were considered significant for p<0.05. 
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PART I: ACTIVITY OF THE PAN-CLASS I PHOSPHOINOSITIDE 
3-KINASE INHIBITOR NVP-BKM120 IN T-CELL ACUTE 
LYMPHOBLASTIC LEUKEMIA 
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4. RESULTS 
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4.1. BKM120 decreases the viability of T-ALL cell lines in vitro by promoting 
apoptosis  
We first evaluated the baseline expression levels of critical components of the PI3K/Akt 
pathway in T-ALL cell lines by western blotting analysis. Despite some heterogeneity, all 
the T-ALL cell lines expressed the PI3K isoforms p110α, β, δ, γ (Figure 7 A). Importantly, 
all cell lines displayed phosphorylated Akt, which is indicative of constitutive activation of 
PI3K signaling pathway (Figure 7 A). Moreover, as previously reported89 and according to 
the presence of cell line gene mutations as reported in the COSMIC database 
(cancer.sanger.ac.uk)156, we confirmed the absence of PTEN protein expression in most 
T-ALL cell lines analyzed, except for BE-13, DND-41 and HPB-ALL. However, in these 
three cell lines PTEN was phosphorylated at Ser380, a marker of PTEN posttranslational 
inactivation and consequent PI3K pathway activation23. To assess the cytotoxic effects of 
BKM120, T-ALL cell lines were incubated with increasing concentrations of the drug for 24 
and 48 h. Cell viability decreased in a concentration-dependent fashion and the IC50 
values ranged between 1.4 and 5.3 µM at 24 h and 0.9 and 5.5 µM at 48 h (Figures 7 B 
and C). Because in a phase I clinical study the maximum tolerated dose of BKM120 
resulted to be 100 mg/d, corresponding to a maximum plasma concentration (Cmax) of 
about 2 µM after the first day treatment and 4 µM at the steady-state132, for subsequent 
experiments we have not exceeded these concentrations. Because effects on cell viability 
may result either from cell death or cell cycle arrest, we then investigated both these 
aspects. 
To evaluate whether the effects of BKM120 on cell viability could be related to apoptosis, 
flow cytometric analysis was performed. In response to treatment with 2 µM BKM120, we 
detected a statistically significant increase in the percentage of early apoptotic (single-
positive for Annexin V) and/or late apoptotic (Annexin V and PI double-positive) cells after 
either 24 or 48 h of treatment (Figure 7 D). Apoptosis was further investigated by western 
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blotting, which revealed a time- and concentration-dependent cleavage of caspase-9, -3 
and -2 (Figure 7 E).  
 
4.2. BKM120 blocks T-ALL cell cycle progression at the G2/M phase 
We next evaluated the effect of BKM120 on cell cycle progression. Analysis of PI-stained 
T-ALL cells treated with 2 µM BKM120 documented the occurrence of a block in the G2/M 
phase of the cell cycle in almost all the tested cell lines at 24 h of treatment (Figure 8 A). 
Comparison with the untreated cells revealed a dramatic increase from 20% to 50% in 
G2/M cells, with a consequent reduction of G0/G1 and S phase cells. Then, cell cycle arrest 
was followed by apoptosis, as documented by the increase in the subG1 cell population at 
later times of treatment (Figure 8 B, MOLT-4 cells). CEM-R cells were the only exception, 
immediately showing a significant increase in subG1 cells, indicating rapid induction of cell 
death (Figure 8 A). Of note, CEM-S and DND-41 cells remained in the G2/M phase of the 
cell cycle up to 72 h of treatment, without cell death induction, in accordance with the low 
apoptotic-rate detection by Annexin V/PI staining (Figure 8 B, DND-41 cells). 
 
4.3. BKM120 affects the PI3K pathway in T-ALL cell lines  
To assess the effects of BKM120 on the PI3K pathway, we analyzed the expression and 
activation of key downstream targets in our panel of leukemic cell lines. We detected a 
concentration- and time- dependent decrease of Ser473 p-Akt and Ser235/236 p-S6RP 
(S6 ribosomal protein) in all the cell lines, while total proteins levels were unaffected, 
confirming the effectiveness of the drug in inhibiting PI3K activity (Figure 9 A). Of note, 
CEM-S, CEM-R and Jurkat cell lines also displayed reduced levels of Thr37/46 p-4E-BP1 
[eukaryotic translation initiation factor (eIF)-4E-binding protein 1] indicating full inhibition of 
mTORC1 activity which leads to oncogenic protein synthesis impairment (Figure 9 B). 
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Moreover, BKM120 did not induce the activation of alternative and Akt-related cell 
proliferation pathways such as Raf/MEK/ERK158, as documented by the unchanged levels 
of phosphorylated, active, Erk1/2 in both Jurkat and DND-41 cells (data not shown). 
 
4.4. BKM120 retains most of its pro-apoptotic activity also in the presence of bone 
marrow stromal cells 
Mesenchymal stromal cells (MSCs) are important components of the bone marrow (BM) 
niche which supports and maintains hematopoietic stem cells (HSCs) but also leukemic 
stem cells (LSCs) through similar interactions159. MSCs are intrinsically resistant to most 
chemotherapeutic agents160 and therefore may protect LSCs against chemotherapy-
induced apoptosis. Hence, we investigated this issue by analyzing by flow cytometry the 
pro-apoptotic activity of BKM120 in Jurkat cells co-cultured with MS-5 murine stromal cells. 
As documented in Figure 10 A, BKM120 induced apoptosis in about 70% of Jurkat cells 
cultured alone. When co-cultured with MS-5 cells, the percentage of apoptotic Jurkat cells 
was reduced to around 50%, indicating that the drug retained a significant cytotoxicity also 
under these conditions (Figure 10 B). Of note, the PI3K/Akt pathway was activated in MS-
5 cells (data not shown), and BKM120 was able to partially affect MS-5 cell survival, as it 
induced apoptosis in about 20% of cells (Figure 10 B and C). Thus, also this effect of 
BKM120 on stromal cells could be important for leukemia cell eradication. 
 
4.5. BKM120 is cytotoxic to and inhibits the PI3K pathway in primary T-ALL blasts 
To better assess the potential therapeutic value of BKM120 in T-ALL, we analyzed six 
pediatric T-ALL patient samples isolated from either BM or peripheral blood. The sensitivity 
of blast cells to BKM120 was evaluated using MTT assays and flow cytometry. After 72 h 
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of treatment with increasing concentrations of BKM120, cell viability was markedly reduced 
in all patient samples analyzed (n=6), with IC50 values ranging between 1.04 and 5.25 µM 
(Figures 11 A and B). Flow cytometric and western blotting analysis revealed high levels of 
Ser473 p-Akt and Ser235/236 p-S6RP in untreated samples, indicating the constitutive 
activation of the PI3K pathway in these patients. Treatment with 2-4 µM BKM120 for 24 h 
induced a considerable decrease in the levels of these phosphorylated proteins and 
partially reduced p-4EB-P1 levels (Figure 11 C and D), indicating a potent inhibition of 
PI3K pathway. Finally, Annexin V-FITC/PI staining documented the presence of apoptotic 
cells following drug administration (Figure 11 E). Overall, these findings demonstrate that 
BKM120 has potent cytotoxic activity against leukemic cells from T-ALL patients displaying 
constitutive PI3K activation.  
 
4.6. BKM120 is synergistic with chemotherapeutics agents in primary T-ALL 
samples 
We further investigated whether BKM120 could synergize with chemotherapeutic agents 
commonly used in T-ALL therapy regimens. For this purpose, patients lymphoblasts were 
treated with increasing concentrations of vincristine or doxorubicin, either alone or in 
combination with BKM120 at fixed ratios (vincristine/BKM120, 1:100 and 
doxorubicin/BKM120 1:2). The synergistic effect was particularly evident with the 
BKM120/doxorubicin combination, that displayed CIs < 0.3, indicating a strong synergism 
(Figure 12 A). In contrast, with the BKM120/vincristine combination, a milder synergism 
(CIs >0.3) was observed.  
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4.7. BKM120 targets the T-ALL SP 
LSCs represent a rare population of the leukemic clone which potentially can reconstitute 
the tumor after a successful therapy due to their self-renewing capacity161. LSCs share 
with the normal HSC counterpart different characteristics, including the expression of ABC 
transporter protein family members, among which ABC subfamily G member 2 (ABCG2) is 
one of the most important and well characterized162. The high expression of these 
transporters enables a flow cytometric identification of these cells as SP, which is 
characterized by a low retention of vital dyes163. We identified the SP in primary T-ALL 
blasts using the Vybrant® DyeCycle. As a control, ABC transporter activity was inhibited 
using Verapamil hydrochloride (Figure 12 B and C). In untreated samples, about 10% of 
SP cells were Annexin V-positive. After 24 h of treatment with BKM120, about 50% of SP 
cells were apoptotic (i.e. Annexin V-positive), thus documenting the ability of BKM120 to 
target the SP. 
 
4.8. BKM120 delays T-ALL tumor growth in vivo 
The significant in vitro antitumor activity of BKM120 on T-ALL cells led us to investigate its 
anti-leukemic efficacy in animal models. NOD/SCID mice were injected subcutaneously 
either with DND-41.Luc.GFP or MOLT-4.Luc.GFP cells. At day 5 after cell transfer, mice 
were equally distributed according to tumor burden in 2 groups to receive 40mg/Kg of 
BKM120 or vehicle control. For both cell lines we observed a significant delay in tumor 
growth in the BKM120-treated group (Figure 13 A), resulting in prolonged survival of 
treated mice (Figure 13 B). Treatment was well tolerated as indicated by the maintenance 
of body weight and the lack of other signs of toxicity (data not shown). To confirm the in 
vivo effects of BKM120 on the PI3K pathway, mice were sacrificed 1 hour after BKM120 
treatment at day 40 (for DND-41.Luc.GFP cells) or day 50 (for MOLT-4.Luc.GFP cells) 
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after cell transfer and cell lysates were obtained from the tumor mass. In both cell lines a 
significant reduction in the phosphorylation levels of Ser473 p-AKT and Ser235/236 p-
S6RP was observed (Figure 13 C and D), showing that BKM120 effectively blocks the 
aberrant activity of the PI3K signaling pathway in vivo. 
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4.9. Figures 
 
Figure 7: BKM120 induces apoptosis of T-ALL cell lines with constitutively active PI3K/Akt pathway. (a) Western blot analysis of 
T-ALL cell lines to detect the expression levels of the class I PI3Ks isozymes, and the expression/phosphorylation of both the PI3K 
regulator PTEN and the PI3K downstream target, Akt. (b) IC50 values obtained through MTT assay (c) after 24 and 48 h treatment 
with increasing concentration of BKM120 (bars, SD). (c) Flow cytometric analysis of Annexin V-FITC/PI–stained T-ALL cells treated 
with 2 µM of BKM120 for 24 and 48 h documented a significant increase in apoptotic cells with respect to untreated cells. 
Asterisks indicate statistically significant differences with respect to untreated cells (*: p < 0.05; **: p < 0.005). (d) Western 
blotting demonstrated a concentration- and time-dependent cleavage of caspases-2, -3 and -9, in agreement with the intrinsic 
apoptotic pathway activation.  
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Figure 8: BKM120 arrests cell cycle at the G2/M phase. (a) Flow cytometric analysis of PI-stained cells revealed an increase in the 
G2/M cell fraction in seven out of eight cell lines induced by treatment with 2 µM of BKM120 for 24 h. Results are the mean of 
three different experiments ± SD. Asterisks indicate statistically significant differences with respect to untreated cells (**: p < 
0.005). (b) Cell cycle time-course analysis. Similar results were obtained in CEM-S cells (not shown). Ctr, untreated cells. 
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Figure 9: BKM120 cytotoxicity is related to PI3K pathway inhibition. Cells were cultured for different times in the presence of 
increased concentrations of BKM120, as indicated, and western blot analysis was then performed. BKM120 induced a 
concentration- and time-dependent dephosphorylation of the main PI3K downstream targets Akt, S6RP (a) and 4EB-P1 (b). 
 
 
Figure 10: BKM120 overcomes the protective effects induced in Jurkat cells by co-culturing with MS-5 stromal cells, which mimic 
the bone marrow microenvironment. (a) Flow cytometric analysis of Annexin V-FITC in Jurkat cells maintained as suspension 
cultures and treated for 48 h with 4 µM BKM120. (b) Flow cytometric analysis of Annexin V-FITC/CD45-PE staining of Jurkat cells 
(CD45+) growing in a co-culture system with MS-5 cells (CD45-) and treated with BKM120, evidenced the persistence of 
apoptosis induction nearly to 50% (C2 quadrant). Cells in C4 quadrant are apoptotic MS-5 cells (CD45-). (c) Flow cytometric 
analysis of Annexin V-FITC staining of MS-5 cells cultured alone with BKM120. Ctr, untreated cells.  
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Figure 11: BKM120 is cytotoxic to primary lymphoblasts from T-ALL patients (Pt) with activated PI3K signaling. (a) MTT assays of 
T-ALL blasts treated with BKM120 for 72 h and (b) IC50 values. (c) Flow cytometric analysis revealed a mean decrease of p-Akt 
and p-S6RP staining levels of 41.62% and 42.42%, respectively, in reponse to 2 µM BKM120 treatment for 24 h (p < 0.0005). Ctr, 
untreated cells. (d) Western blot analysis confirmed a concentration-dependent decrease in p-Akt and p-4E-BP1 levels in primary 
cells treated with BKM120. (e) Flow cytometric analysis of Annexin V-FITC/PI–stained patients blasts treated for 24 h with 
BKM120 documented a significant increase in the apoptotic cells. A representative patient is shown. Ctr, untreated cells. 
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Figure 12: Synergistic effects of BKM120 with conventional chemotherapeutic agents and efficacy on the SP in primary T-
lymphoblasts. (a) MTT assays of patient T-lymphoblasts treated for 72 h with BKM120 alone or in combination with vincristine or 
doxorubicin at a fixed ratio. The combined treatments resulted in a strong synergism (CIs 0.1-0.3), synergism (CIs 0.3-0.7) or 
moderate/slight synergism (CIs 0.7-0.9). (b and c) Flow cytometric analysis of SP in primary T-lymphoblasts cultured in the 
absence (b) or presence (c) of 1 µM BKM120 for 24 h. Cells were stained with the Vybrant® DyeCycle in the absence or the 
presence of Verapamil (50 µM). The SP, which disappeared in the presence of Verapamil, was gated and Annexin V-FITC staining 
evaluated. In BKM120-treated samples (c) about 50% of the SP cells resulted apoptotic, while only about 10% of the SP cells 
were apoptotic in untreated samples (b), indicating that BKM120 is able to efficiently target the SP. 
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Figura 13: BKM120 delays T-ALL tumor growth and prolongs survival of transplanted mice through inhibition of the PI3K 
pathway. NOD/SCID mice were injected subcutaneously with 10x106 DND-41.Luc.GFP or MOLT-4.Luc.GFP cells in each flank. Five 
days after cell transfer, mice were equally distributed according to tumor burden in 2 groups (n=6 per group): Control (vehicle 
control) and BKM (BKM120, 40mg/Kg, po, daily). (a) Tumor volume was assessed at the indicated time points after cell 
transplantation for mice receiving DND-41.Luc.GFP (left) or Molt-4.Luc.GFP (right) cells. Statistical differences were evaluated 
using two-way ANOVA. Control and BKM120-treated groups presented a significant difference in tumor development for both 
cell lines (p < 0.0001, two-way ANOVA). (b) Survival curves for Control and BKM120-treated mice transplanted with DND-
41.Luc.GFP, considering a 2000 mm3 tumor volume cut-off. Survival time was significantly increased in the BKM120-treated 
group (p = 0.0062, LogRank test). (c) Mice transplanted with DND-41.Luc.GFP or MOLT-4.Luc.GFP cells were sacrificed at day 40 
or 50, respectively, after cell transplantation, 1 hour after vehicle or BKM120-treatment. Cell lysates were obtained from the 
tumor mass and immunoblotted with antibodies against Ser473 p-Akt, Ser235/236 p-S6RP or β-Actin as loading control. (d) 
Corresponding densitometric analysis of p-Akt and p-S6RP, normalized to β-Actin loading control (p = 0.009 for p-Akt and p = 
0.018 for p-S6RP, unpaired t test). 
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5. DISCUSSION 
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Despite continuous efforts to uncover the molecular complexity of T-ALL, treatments are 
still based on chemotherapeutic regimens, and prognosis of this disease remains poor, 
especially in the adult and in chemoresistant/relapsed patients. In view of the critical role of 
PI3K/Akt signaling in T-ALL cell homeostasis, the activity of the pan-PI3K inhibitor 
BKM120 was examined in T-ALL cell lines and in primary T-ALL lymphoblasts. Studies 
were performed both in vitro and in vivo. BKM120 reduced cell viability in a concentration-
dependent manner in all the tested cell lines and primary patient samples. In a phase I 
clinical study, the maximum plasma concentration (Cmax) of BKM120 obtained after 
administration of the maximum tolerated dose of the drug was 4 μM132. Interestingly, 9 out 
of 10 of the T-ALL cell lines tested in our study displayed an IC50 below the Cmax, and 5 of 
6 patient samples displayed a clinically achievable IC50, encouraging BKM120 application 
in T-ALL. The BKM120 cytotoxic effects correlated with a significant induction of apoptosis 
and cleavage of caspases-9, -3 and -2, suggesting the activation of the intrinsic apoptotic 
pathway. In agreement with previous findings in other cancers165-166, treatment with 
BKM120 induced cell cycle arrest in G2/M phase in 7 out of 8 T-ALL cell lines, suggesting 
an impairment in mechanisms involved in cell cycle progression and mitosis regulation. 
This condition presumably induces accumulation of DNA damage167-168, which finally leads 
to cell death, as evidenced by the increase in the subG1 cell fraction which followed cell 
cycle block. To determine whether the cytotoxic effects observed in our study were related 
to BKM120-induced PI3K inhibition, we investigated the phosphorylation status of Akt, a 
direct downstream target of PI3K, as well as that of S6RP in T-ALL cell lines and primary 
samples. In all cell lines and primary samples, BKM120 inhibited Akt phosphorylation on 
Ser473 and S6RP phosphorylation on Ser235/236. Although we cannot exclude that the 
drug concentrations used in our in vitro studies may lead to off target effects in T-ALL 
cells, namely by inhibiting microtubule dynamics by direct binding of BKM120 to tubulin169, 
our data are consistent with a major direct effect on PI3K/Akt signaling pathway. Indeed, 
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BKM120 was effective also in T-ALL primary cells, that are mostly blocked in the G0/G1 
phase of the cell cycle, hence not susceptible to alterations of microtubule dynamics 
during the G2/M phase of the cell cycle. It is also worth emphasizing that BKM120 induced 
dephosphorylation of 4E-BP1. Phosphorylation of the translation repressor 4E-BP1 is the 
limiting step for the assembly of the translation initiating complexes which are especially 
important for oncogenic protein synthesis157, 170. Therefore, drugs that target 4E-BP1 are 
considered more effective in cancer therapy than molecules that do not affect it, such as 
rapamycin/rapalogs157. The difficulty in eradicating acute leukemias might result from the 
conventional treatments targeting the bulk of the leukemic cells, but not the LSCs, which 
are postulated to be the cause of relapse171. Therefore, strategies that eliminate these 
cells could have significant clinical implications. Remarkably, we have documented that 
BKM120 induced apoptosis in the T-ALL patient SP, which is likely enriched in LSCs. This 
observation might be of relevance, since an efficient targeting of these cells could lead to 
leukemia eradication. In addition, it has been suggested that stromal cells of the leukemic 
stem cell niche exert a protecive effect on LSCs171. Interestingly, BKM120 retained most of 
its pro-apoptotic activity even when Jurkat cells were co-cultured with MS-5 murine bone 
marrow stromal cells, which partly mimic the leukemic bone marrow microenvironment. 
Also of note, we demonstrated that combination of BKM120 with either doxorubicin or 
vincristine, commonly used drugs in T-ALL treatment172, was clearly synergistic. This 
finding may be of significance in the clinical setting in the future. 
Further evaluation of the clinical potential of BKM120 in T-ALL, using xenotransplant 
mouse models of T-ALL, demonstrated that the PI3K inhibitor can clearly retard tumor 
development, without obvious side-effects. Moreover, although we cannot rule out off 
target in vivo impacts, the dose we administered is consistent with essentially on-target 
effects169 and our molecular analyses confirmed that BKM120 effectively inhibits PI3K-
mediated signaling in the tumor mass, as evidenced by decreased p-Akt and p-S6RP 
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levels. Interestingly, p-S6RP levels have been used previously as a read-out for proving 
BKM120 efficacy in patients132. Whether, in agreement with our observations in vitro, 
BKM120 synergizes in vivo with currently used chemotherapeutic drugs warrants further 
investigation. A recent paper, has highlighted that in PTEN-null models of murine T-ALL, 
genetic inactivation of both p110γ and p110δ PI3Ks suppressed tumor formation. 
Consistently, a dual p110γ/p110δ inhibitor reduced disease burden and prolonged survival 
in mice. The dual inhibitor was also effective against human T-ALL cell lines and primary 
samples, although in this case the dependence of the cytotoxic effects on the absence of 
PTEN was much less evident146. However, our preliminary results indicated that, at least in 
T-ALL cell lines, BKM120 was much more effective in inducing cytotoxicity than a 
combined inhibition of p110γ and p110δ isoforms (data not shown), suggesting that also 
p110α and p110β isozymes may play a role in T-ALL cell proliferation and survival, as 
previously reported173. Our observations have been confirmed in a recent paper which 
documented that only pan inhibition of PI3K was able to suppress Akt phosphorylation and 
to significantly reduce the proliferation of T-ALL cell lines 174. Furthermore, even in pre-
clinical models of B-CLL, i.e. a disease where the use of p110δ PI3K inhibitors has been 
strongly advocated175, the in vitro cytotoxicity of BKM120 against malignant B-CLL 
lymphocytes was much stronger (at 3.6 fold) than that of CAL-101, a selective p110δ PI3K 
inhibitor144. 
Taken together, our pre-clinical study provided evidence of the effectiveness of BKM120 in 
T-ALL as a single agent or in combination with doxorubicin and vincristine. The drug 
showed high antitumor activity against T-ALL cell lines and primary leukemia blasts from 
T-ALL patients. In conclusion, BKM120 is a promising treatment option for T-ALL and our 
findings support its clinical evaluation in this malignancy. 
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PART II: PAN-PI3K INHIBITION IMPAIRS MORE EFFICIENTLY 
PROLIFERATION AND SURVIVAL OF T-CELL ACUTE 
LYMPHOBLASTIC LEUKEMIA CELL LINES WHEN COMPARED 
TO ISOFORM-SELECTIVE PI3K INHIBITORS 
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6. RESULTS 
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6.1. In vitro assessment of PI3K inhibitors effects on cell viability 
In order to establish the role of the different PI3K catalytic subunits in supporting leukemic 
cells proliferation and survival, we exploited a pharmacological approach by using 
selective inhibitors together with dual p110γ/δ and pan inhibitors. The pan inhibitor 
BKM120 has been evaluated in both preclinical leukemic models129 and phase I clinical 
trials for patients with solid tumors130-132, whereas ZSTK-474133-135 and PIK-90147 efficacy 
has been assessed only in preclinical models. To specifically inhibit p110α, p110β, p110δ 
and p110γ we employed A-66, TGX-221, CAL-101 and AS-605240, respectively, whose 
selectivity has been elsewhere reported146-147,176, and that at least in some settings have 
shown effectiveness in hematological malignancies137. Because of the prominent role of 
p110δ and p110γ isoforms in T-lymphocytes55, effects of the dual inhibitor IPI-145 as well 
as the combination of CAL-101 plus AS-405260 were also evaluated. Cells were cultured 
with increasing concentration of the drugs for 48 h followed by metabolic activity 
assessment by MTT assay (Figure 14 A and C). In both PTEN deleted (Jurkat and Loucy) 
and PTEN non deleted (DND-41 and ALL-SIL) cells, growth rate diminished after 
treatment with BKM120 and ZSTK-474 with IC50 values ranging between 1.05-2.34 µM for 
BKM120 and 0.99-3.39 µM for ZSTK-474. Conversely, PIK-90 mildly affected these cells, 
with the exception of Loucy cells (IC50 0.096 µM). As expected, selective inhibition of 
p110α, p110β, p110δ and p110γ isoforms resulted ineffective, with IC50 values not attained 
at the tested concentrations. We further investigated the effectiveness of combining p110δ 
and p110γ inhibitors, by treating T-ALL cell lines with CAL-101 and AS-405260 at a fixed 
ratio (1:1). As shown in Fig. 14 (B and D), these two inhibitors resulted in a strong (CI < 
0.3) to moderate (CI < 0.9) synergism in ALL-SIL, Loucy and Jurkat at concentrations 
above 1 µM, whereas in DND-41 combination of CAL-101 and AS-605240 did not exert a 
synergistic but an antagonistic (at 1 and 2 µM) or additive (at 4 and 8 µM) effect. 
Nevertheless, IC50 values achieved by the combination were higher compared to those of 
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pan inhibitors (Figure 14 C). Interestingly, the dual p110γ/δ inhibitor IPI-145 had an effect 
only on Luocy cells. Overall, pan inhibition resulted more efficient to affect T-ALL cell 
viability with regard to specific as well as dual p110γ/δ inhibition. Based on these results, 
we selected ZSTK-474 as pan inhibitor and we used the concentration of 5 µM for the 
following experiments to simplify comparison of the results obtained with the different 
inhibitors. 
 
6.2. Pan PI3K inhibition affected proliferation in a PTEN-independent fashion 
We investigated more in detail the role of PI3K pathway inhibition on cell proliferation 
observing the long-term cell growth over 3 days post treatment. The pan inhibitor ZSTK-
474 significantly impaired cell proliferation in all the cell lines, independently from PTEN 
status, whereas p110α and p110β inhibition produced negligible effects (Figure 15 A). 
Specific and dual inhibition of p110γ and p110δ isoforms displayed an irregular trend. 
Jurkat and DND-41 proliferation was unaffected by their inhibition, conversely in Loucy and 
ALL-SIL p110δ or dual p110γ/δ significantly impaired cell growth (Figure 15 A). Compared 
to untreated controls, ZSTK-474 strongly slowed down the doubling time in Loucy, DND-41 
and ALL-SIL cells, whereas a negative doubling time was estimated in Jurkat cells, 
suggesting cell death induction (Figure 15 C). Importantly, in Loucy cells, the only one cell 
line responsive to IPI-145, proliferation was impaired already at 0.5 µM after treatment with 
this dual inhibitor (Figure 15 B and C).  
To ascertain that the observed effects of ZSTK-474 on cell growth rate were due to a 
proliferative impairment, we also evaluated the expression of the proliferation marker Ki-
67, a nuclear antigen present throughout the cell cycle. In accordance with growth curves 
analyses, Ki-67 decreased broadly in all the cell lines after 72 h treatment with the pan 
inhibitor ZSTK-474 (Figure 15 D).  
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These results demonstrated that PI3K pan inhibition impaired cell proliferation more 
efficiently than dual p110γ/δ inhibition and supported its highest anticancer activity.  
 
6.3. Antiproliferative effects are independent from total PtdIns(3,4,5)P3 level 
reduction 
To evaluate the impact of the inhibitors on PI3K activity, total PtdIns(3,4,5)P3 levels were 
quantified by flow cytometry. Firstly, we investigated cell lines with regard to PI3K isoforms 
and PTEN expression. As shown in Figure 16 A, the catalytic subunits p110α, -β, -γ and –
δ, target of the PI3K inhibitors, were expressed in control as well as treated samples. As 
expected, PTEN protein was absent in deleted Jurkat and Loucy cells, but abundantly 
expressed and unaffected by treatments in non deleted ALL-SIL and DND-41 cells. 
Nevertheless, in both of these cell lines, PTEN resulted phosphorylated at Ser380, which 
is a marker of PTEN posttranslational inactivation and consequent PI3K pathway 
activation89. This observation could explain the absence of differences among the two cell 
line groups, PTEN deleted and non deleted. 
Flow cytometry analysis of untreated samples showed different basal levels of 
PtdIns(3,4,5)P3 irrespective of PTEN status, with an amount in deleted Jurkat and non 
deleted DND-41 approximately of 48% and 45%, respectively, and 77% vs 75% in deleted 
Loucy vs non deleted ALL-SIL (Figure 16 B). Interestingly, after 6 h treatment, in all cases 
the compounds induced a decrease of the second messenger, demonstrating that each 
PI3K catalytic isoform contribute to PtdIns(4,5)P3 phosphorylation in T-ALL cells (Figure 16 
C). While in Jurkat cells all the inhibitors drastically decreased PtdIns(3,4,5)P3, the other 
cell lines displayed significantly decreased PtdIns(3,4,5)P3 only in response to some 
treatments (CAL-101 in DND-41; A-66, AS-605240 and combination of AS-605240 plus 
CAL-101 in ALL-SIL; A-66, CAL-101 and combination of AS-605240 plus CAL-101 in 
Loucy). Importantly, pan inhibition was able to induce a significant reduction of 
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PtdIns(3,4,5)P3 in all cell lines. Moreover, PtdIns(3,4,5)P3 decreased in a concentration-
dependent fashion in Loucy cells treated with the dual p110γ/δ inhibitor IPI-145 (0.5, 1 and 
5 µM; Figure 16 B). These observations suggested a peculiar addiction to PI3K isoforms of 
the different cell lines with regard to PtdIns(4,5)P3 phosphorylation, suggesting a potential 
influence of cellular-specific mechanisms in PtdIns(3,4,5)P3 generation. However, both 
PtdIns(3,4,5)P3 basal level and PtdIns(3,4,5)P3 reduction did not correlate with the 
observed antiproliferative effects. We also evaluated the individual contribution of p110α, -
β, -γ and -δ to PtdIns(3,4,5)P3 levels, by treating the cells with a combination of three 
different selective inhibitors. Nevertheless, results showed only the reduction of 
PtdIns(3,4,5)P3, but in no cases we observed the complete abrogation of the second 
messenger, supporting a role for each isoform in PtdIns(3,4,5)P3 syntesis and PI3K 
pathway activation (data not shown).  
Taken together, these data demonstrated that each isoform can sustain PtdIns(3,4,5)P3 
synthesis in T-ALL, but its total intracellular amount is not directly related to cellular 
proliferation.  
 
6.4. Pan inhibition of PI3K and PtdIns(3,4,5)P3 decreases Akt-mediated signaling 
We next examined the effects of the different isoforms inhibition to understand their role in 
PI3K signaling. One of the major PI3K target is the serine/threonine kinase Akt, which is 
recruited to the plasma membrane through direct interaction with PtdIns(3,4,5)P3 and 
subsequent phosphorylation on Thr308 by PDK1 and Ser473 by mTORC2 for fully 
activation. In all cell line, selective p110α, -β or -γ inhibition was unable to reduce 
Akt(Thr308) phosphorylation, whereas p110δ and dual p110γ/δ inhibition both induced a 
comparable decrease, suggesting a major role for p110δ isoform in Akt activation (Figure 
17 A). Conversely, pan inhibition exerted the strongest effect on Akt activation, with a 
complete abrogation of phosphorylation at Thr308. Most importantly, only pan PI3K 
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inhibition induced a significant reduction of p-Ser473 in all the cell lines, which is essential 
for switching off Akt signaling, already after 6 h (Jurkat, Loucy and DND-41; Figure 17 A) 
or 24 h (ALL-SIL; Figure 17 B) treatment. Analysis of Akt downstream targets showed a 
congruent pattern of dephosphorylation, with the decrease of p-P70S6K both 
Thr421/Ser424 (auto-inhibitory domain) and Thr389 (mTORC1 phosphorylation site), and 
p-S6RP(Ser235/236), after pan or, to a lesser extent, dual p110γ/δ inhibition (Figure 17 A). 
These results confirmed PI3K pathway inhibition. In all cases, total proteins levels were 
unaffected. Consistently with cell viability and proliferation analyses, only in the Loucy cell 
line repression of p110γ/δ with the dual inhibitor IPI-145 was effective and displayed a 
concentration-dependent trend of pathway inhibition (Figure 17 A). To assess if other 
targets beyond Akt could be affected by PI3K inhibition and PtdIns(3,4,5)P3 decrease, we 
further investigated PDK1 together with several of its downstream targets, PKCα and 
PKCβ. We observed that neither specific, dual or pan inhibitors reduced phosphorylated 
levels of these proteins, in agreement with their PtdIns(3,4,5)P3 independent and PDK1 
dependent mechanism of activation 177. Therefore, block of PI3K activity mainly inhibits 
PtdIns(3,4,5)P3 dependent Akt pathway. 
 
6.5. Aniproliferative activity of pan PI3K inhibition acts through cell cycle arrest 
and caspase-independent cell death 
Next, we investigated the mechanisms likely involved in proliferation impairment. Because 
PI3K/Akt signaling mediates different cellular pathways, we examined the effects on cell 
cycle and induction of apoptosis. Cell cycle phase distribution strongly changed in all cell 
lines as a result of pan-inhibition (ZSTK-474 treatment for 48 h) (Figure 18 A). Flow 
cytometry analysis showed an accumulation of cells in G0/G1 and consequent decrease of 
S or G2/M cell phase, as previously reported 
134, which reached a statistical significance in 
ALL-SIL and DND-41 cells. Moreover, in Jurkat, Loucy and ALL-SIL cells ZSTK-474 
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increased the subG1 cell fraction, which comprises death cells. Lesser effects were 
observed with the other inhibitors, which affected only ALL-SIL and Loucy cells. In ALL-SIL 
cells, selective-isoform inhibitors and the combination of AS-605240 and CAL-101 induced 
an accumulation of G0/G1 cells and a consequent reduction of S or G2/M cells, without 
affecting subG1 cell phase. Combination of AS-605240 and CAL-101 inhibition altered cell 
cycle phase distribution in Loucy cells, inducing the expansion of G0/G1 fraction. However, 
the dual γ/δ inhibitor IPI-145 had no effects. 
Annexin V-FITC/PI analysis confirmed a significant increase of apoptotic cells following 
treatment with ZSTK-474 for 48 h in all the cell lines, whereas dual p110γ/δ inhibition had 
limited effects, inducing significant cell death only in the Loucy cell line (Figure 18 B). 
Western blot  analysis revealed the absence of cleaved effector caspase 3  both at 24 and 
48 h treatment  (Figure 18 C and data not shown), suggesting that caspases did not 
contribute to cell death. To prove that, we treated these cells with ZSTK-474 in the 
presence or absence of the polycaspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone, z-VAD-fmk. As shown in Figure 18 D, cell death induced by pan PI3K 
inhibition not only was not affected by caspases inhibition, but in some instances it was 
even increased.  
Overall, these results demonstrated as PI3K inhibition caused cell cycle arrest in G0/G1 cell 
phase, but only pan inhibition was able to efficiently induce cell death with a caspase 
independent mechanism. 
  
6.6. Autophagy is a protective mechanism against pan PI3K inhibition  
Autophagy is a homeostatic cellular process which regulate protein and organelle turnover 
by lysosomal destruction178. This process would also execute cell demise, and autophagic 
cell death is one of the better recognized independent programmed cell death 
mechanisms 179. With respect to autophagy induction, we investigated the expression of 
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LC3B I/II, a recognized autophagy marker 180. Western blot analysis showed a strong 
increase in LC3B II, the lower migrating form of the protein which is bound to the 
autophagosome membranes, in Loucy, ALL-SIL and DND-41 cells especially following 24 
h ZSTK-474 treatment, whereas almost no changes were observed in Jurkat cells (Figure 
19 A). Because pan PI3K inhibition with ZTK-474 treatment induced a considerable 
percentage of apoptosis in Jurkat compared to the other cell lines, we supposed a 
protective role of autophagy in this context. To test our hypothesis, we inhibited autophagy 
with the early-stage autophagy inhibitor 3-methyladenine (3-MA) and subsequently 
evaluated cell death percentage induced by treatment with the pan inhibitor ZSTK-474. 
The results demonstrated that addiction of 3-MA increased the cytotoxic effect of pan PI3K 
inhibition, since the percentage of Annexin V/PI positive cells was significantly greater in 
Loucy, ALL-SIL and DND-41 cells compared to samples treated with ZSTK-474 alone 
(Figure 19 B). On the contrary, in Jurkat cells, where PI3K inhibition did not induce LC3B 
lipidation, inhibition of autophagy did not increase cytotoxicity (Figure 19 B). The same 
results have been obtained with the autophagy inhibitors bafilomycin A1 or E64D (data not 
shown). To ascertain whether the dissimilar behavior between Jurkat and the other cell 
lines was related to a different modulation of autophagy-related genes, a screening for 
gene expression was performed using a quantitative real time-PCR assay which 
interrogates 82 genes related to the autophagy pathway (Table 2 and Figure 19 C). 
Expression of several genes resulted undetectable in both control and treated samples:  
ULK2 and TGM2 in all the cells lines; CDKN2A in ALL-SIL and Jurkat cells; RB1 and APP 
in ALL-SIL cells; ESR1 in Jurkat cells. Unsupervised hierarchical clustering showed 
similarities in autophagy gene expression in each paired cell line (untreated and treated 
samples) (Figure 19 C). Moreover, untreated Loucy cells showed a higher expression of 
these genes compared to the other samples. However, no transcripts differentially 
clustered in Jurkat cells, despite this cell line did not activate the autophagy process 
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following pan PI3K inhibition. We further investigated the modulation of autophagy, 
comparing untreated and treated samples and assessing for each gene the fold change, 
expressed as 2-∆∆Ct. A 24 h treatment with ZSTK-474 had limited effects on autophagy at a 
transcriptional level, as the majority of genes resulted expressed equally to the control (2-
∆∆Ct = 1) or slightly reduced (2-∆∆Ct < 1), especially in Loucy cells (Figure 6 C). Nevertheless, 
in some instances we observed a > 2 fold increase both in components of the autophagy 
machinery and in genes involved in autophagy regulation (Table 3 and Figure 19 D). In 
particular, in Loucy, ALL-SIL and DND-41 cells, pan PI3K inhibition increased expression 
of DRAM1, GABARAPL1, GABARAPL2, WIPI1, MAP1LC3B and ATG16L2, all involved in 
autophagic vesicle nucleation and expansion, as well as increased expression of genes 
involved in autophagy induction and regulation (INS, PIK3C) or pro survival genes (BCL2, 
EIF2AK3). On the contrary, in Jurkat cells pan PI3K inhibition had limited effects on 
autophagy induction, as the only upregulated gene was ULK1. However, we observed a > 
2 fold change in expression of the tumor suppressor genes CDKN1B and TP53, and CTSS 
(cathepsin S) which deficiency has been associated to alterations in autophagic flux 181. 
These results demonstrated that pan PI3K inhibition might induce autophagy which plays a 
protective role in T-ALL cells, and suggested that autophagy activation in the different T-
ALL cell lines might be dependent on a diversified gene expression regulation. 
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6.7. Tables 
Table 2: Autophagy related genes analyzed using Real-time PCR microarrays 
Autophagy Machinery Components 
AMBRA1, ATG10, ATG12, ATG16L1, ATG16L2, ATG3, ATG4A, ATG4B, ATG4C, ATG4D, ATG5, ATG7, ATG9A, 
BECN1, DRAM1, GABARAP, GABARAPL1, GABARAPL2, IRGM, LAMP1, MAP1LC3A, MAP1LC3B, NPC1, 
RAB24, RGS19, ULK1, ULK2, WIPI1 
Regulation of Autophagy 
AKT1, APP, BAD, BAK1, BAX, BCL2, BCL2L1, BID, BNIP3, CASP3, CASP8, CDKN1B, CDKN2A, CLN3, CTSB, 
CTSD, CTSS, CXCR4, DAPK1, DRAM2, EIF2AK3, EIF4G1, ESR1, FADD, FAS, GAA, HDAC1, HDAC6, HGS, 
HSPA8, HSP90AA1, HTT, IFNG, IGF1, INS, MAPK14, MAPK8, MTOR, NFKB1, PIK3CG, PIK3C3, PIK3R4, 
PTEN, RB1, RPS6KB1, SNCA, SQSTM1, TGFB1, TGM2, TMEM74, TNF, TNFSF10, TP53, UVRAG 
 
Table 3: Autophagy related genes upregulated after pan-PI3K inhibition. 
Autophagy Machinery Components 
DRAM1 
DNA-damage regulated autophagy 
modulator 1 
Lysosomal modulator of autophagy induced by p53 
GABARAPL1 
GABA(A) receptor-associated protein like 
1 
essential for autophagosome maturation 
GABARAPL2 
GABA(A) receptor-associated protein-like 
2 
essential for autophagosome maturation 
MAP1LC3B 
Microtubule-associated protein 1 light 
chain 3 beta 
involved in formation of autophagosomes 
ATG16L2 Autophagy related 16-like 2 
May play a role in autophagy during membrane 
biogenesis 
ULK1 unc-51 like autophagy activating kinase 1 
Regulate the formation of autophagophores 
(upstream PIK3C) 
WIPI1 
WD repeat domain, phosphoinositide 
interacting 1 
Required for autophagosome formation 
(downstream ULK1 and PIK3C) 
Regulation of Autophagy 
INS Insulin Peptide hormone 
BNIP3 
BCL2/adenovirus E1B 19kDa interacting 
protein 3 
May positively modulate autophagy  
displacing Bcl-2 from the Bcl-2/Beclin 1 complex 
TNF Tumor necrosis factor Cytokine 
ESR1 Estrogen receptor 1 Regulate autophagy core proteins 
BCL2 B-cell CLL/lymphoma 2 Promote cellular survival 
EIF2AK3 
Eukaryotic translation initiation factor 2-
alpha kinase 3 
Repress global protein synthesis. Critical effector of 
unfolded protein response (UPR) 
IFNG Interferon gamma Cytokine 
PIK3C3 
Phosphatidylinositol 3-kinase, catalytic 
subunit type 3 
Involved in initiation and maturation of 
autophagosomes 
CDKN1B 
Cyclin-dependent kinase inhibitor 1B 
(p27Kip1) 
Cell cycle regulator. Its degradation is required for 
G1 cell phase progression 
TP53 Tumor protein p53 Tumor suppressor 
CTSS Cathepsin S 
Cysteine lysosomal protease involved in autophagic 
flux regulation 
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6.8. Figures 
 
Figure 14: Inhibition of all the PI3K catalytic isoforms exerts the strongest effect on cell viability. (A and B) MTT analysis of PTEN-
deleted (Jurkat, Loucy) and non deleted (ALL-SIL, DND-41) T-ALL cell lines treated for 48 h with increasing concentration of PI3K 
inhibitors. (B) Effect of the combination of AS-605240 and CAL-101 on cell viability. (C) IC50 values obtained through MTT assay 
after 48 h treatment with increasing concentration of PI3K inhibitors. (D) Analysis of the AS-605240 (p110γ inhibior) and CAL-101 
(p110δ inhibitor) combination, which resulted synergistic in Jurkat, Loucy and ALL-SIL (CIs 0.1-0.9). In DND-41 CIs values  > 2 
indicate an antagonistic effect, whereas ICs > 1 are additive. (CI: combination index; Fa: Fraction affected). 
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Figure 15: Pan PI3K inhibition impair proliferation in T-ALL cell lines. Growth curves of T-ALL cell lines treated with 5 μM of PI3K 
selective, dual and pan inhibitors (A) or with increasing concentration (0.5, 1 and 5 μM) of the dual inhibitor IPI-145 (B). Viable 
cells were counted before treatment (0 h), and after 16, 24, 40, 48, 64 and 72 h from treatment. Cell growth was calculated as 
the percentage of viable cells compared to that at T 0 h . Four independent count for each time point and two independent 
experiments for each cell line were performed (bars, SD). (C) Doubling time obtained from the cell count analysis. Increase in 
doubling time indicate impairment of proliferation. The negative doubling time observed in Jurkat cells indicate cell death 
induction. Asterisks indicate statistically significant differences with respect to untreated cells (*: p < 0.05; **: p < 0.01; ***: p < 
0.001). (D) Flow cytrometric analysis of the proliferation marker Ki-67. Cells were treated with 5 μM of the pan inhibitor ZSTK-
474 for 72 h. Upper panel: control cells (untreated). Lower panels: treated cells. 
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Figure 16: Effects of PI3K inhibition on PIP3 synthesis. (A) Characterization of the T-ALL cell. Cells were cultured for 6 h with the 
different inhibitors, as indicated, and western blot analysis was then performed. PTEN-non deleted cell lines express abundantly 
PTEN protein, but it is phosphorylated at Ser380, which is an inhibitory site. Flow cytomety quantification of the second 
messenger PIP3 in untreated cells (B) or following 5 μM of PI3K inhibitors for 6 h (C). Bars, SD. Asterisks indicate statistically 
significant differences with respect to untreated cells (* :p < 0.05; **: p < 0.01; ***: p < 0.001). 
 
 
Figure 17: Pan PI3K inhibition induces the complete block of Akt pathway  Cells were cultured for 6 h (A and C) or 24 h (B) in the 
presence of 5 μM of the different PI3K inhibitors, as indicated, and western blot analysis was then performed. The pan inhibitor 
ZSTK-474 and the combination af p110γ and p110δ inhibitors (AS-605240 and CAL-101) induced the dephosphorylation of the 
main PI3K downstream targets Akt, P70S6K and S6RP (A and B) but only the pan inhibitor ZSTK-474 decreased both the 
phosphorylated residues of Akt, Thr308 and Ser473. Only in Loucy the dual p110γ/δ IPI-145 exerted a dose-dependent activity 
on PI3K downstream targets. (C) PDK1, PKCα and PKCβII proteins were not modulated by inhibition of PI3K. Thirty µg of protein 
was blotted to each lane. Antibody to β-Actin served as a loading control. Molecular weights are indicated at right. Ctr, 
untreated cells.  
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Figure 18: Pan PI3K inhibition affect ell cycle and induce caspase independent cell death (A) Flow cytometry analysis of PI-
stained cells treated with 5 μM of the different PI3K inhibitors (as indicated) for 48 h. The pan inhibitor ZSTK-474 increased the 
subG1 and/or the G0/G1 cell fraction, with the consequent decrease of the other cell phases, whereas the dual p110γ/δ exerted 
limited effects on cell cycle distribution. The dual inhibitor IPI-145 did not perturb cell cycle of the sensitive Loucy cell line. (B) 
Flow cytometric analysis of Annexin V-FITC/PI–stained T-ALL cells treated with 5 µM of the different PI3K inhibitors (as 
indicated) for 48 h documented a significant increase in cell death fraction with respect to untreated cells only after pan PI3K 
inhibition. The dual inhibitor IPI-145 exerted a concentration-dependent effect on Loucy cell line. (C) Western blotting revealed 
that PI3K inhibition did not induce caspase activation. Thirty µg of protein was blotted to each lane. Antibody to β-Actin served 
as a loading control. Molecular weights are indicated at right. (D) T-ALL cells were treated with 5 μM ZSTK-474 for 48 h with or 
without the pan caspase inhibitor z-VAD-fmk (50 μM) and cell death fraction was assessed with Annexin V-FITC/PI staining. 
Caspase inhibition did not affect or even increase cytotoxicity. Results are the mean of three different experiments ± SD. 
Asterisks indicate statistically significant differences with respect to untreated cells (* :p < 0.05; **: p < 0.01; ***: p < 0.001). 
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Figure 19: Pan PI3K inhibition might induce autophagy which plays a protective role. (A) Western blotting revealed autophagy 
activation in Loucy, ALL-SIL and DND-41 cell lines. Thirty µg of protein was blotted to each lane. Antibody to β-Actin served as a 
loading control. Molecular weights are indicated at right. (B) T-ALL cells were treated with 5 μM ZSTK-474 for 48 h with or 
without the autophagy inhibitor 3-MA (200 μM) and cell death fraction was assessed with Annexin V-FITC/PI staining. 
Autophagy inhibition significantly increased cell demise, revealing its protective role in Loucy, ALL-SIL and DND-41 cell lines, 
whereas did not affect Jurkat cells. Results are the mean of three different experiments ± SD. Asterisks indicate statistically 
significant differences with respect to untreated cells (* :p < 0.05; **: p < 0.01; ***: p < 0.001). (C) Real-time PCR expression 
profiling of 82 autophagy related genes in T-ALL cell lines untreated (Ctr) or treated for 24 h with 5 μM ZSTK-474 were visualized 
using an unsupervised heatmap. Data are presented as 2-∆Ct (∆Ct = Ct target gene – Ct RLP0). (D) Histograms represent the 
relative gene expression of several autophagy-related genes in T-ALL cells treated with ZSTK-474 and compared to untreated 
paired sample.  Data are presented as 2-∆∆Ct (∆∆Ct = ∆Ct treated sample – ∆Ct Ctr sample). When fold change values are =1, the 
regulation in treated samples is equal to the paired control sample. When fold change values are >1 or <1, the autophagy related 
genes are up- or downregulated, respectively, compared to untreated samples. 
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7. DISCUSSION 
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PI3K signaling pathway is often deregulated in malignancies and contribute to the 
oncogenic process. The mechanisms responsible for class I PI3Ks activity upregulation 
diverge among the distinct tumors. For example, gain of function mutations in PIK3CA that 
encodes the catalytic subunit p110α, have been detected in a wide variety of human solid 
cancers182, whereas p110δ is implicated in cancers derived from B lymphoid cells183. 
Recently, the oncogenic potential of p110β184 has emerged in breast 185 and prostate 
cancers186. Tumor cells addiction to the activity of specific class I PI3K isoforms has lead 
to the development of efficacious therapies based on the application of selective PI3K 
inhibitors which target selective catalytic subunit187. In T-ALL, PI3K upregulation has been 
found in nearly 80% of cases120 and targeting PI3K is an attractive novel strategy to treat 
these patients. Nevertheless, at present it is still controversial the role played by the 
different PI3K catalytic subunits in T-ALL and therefore which might be the most useful 
therapeutic strategy. It is well established that both p110γ and p110δ, enriched in 
leukocytes, are involved in thymocyte development and activity55. The catalytic subunits 
p110α and p110β are ubiquitously expressed so that it is extremely difficult to dissect their 
roles in lymphocytes, due to the embryonic lethality induced by loss of either p110α or 
p110β188. However, there is a complex interplay between the class I PI3K members, as 
inhibition or loss of a specific isoform might be compensated by the others189. 
Subramanian et al. proposed the predominant role of p110γ and p110δ in PTEN-deleted 
T-ALL, suggesting the possibility to target cancer cells by inhibiting specifically these 
isoforms146. Conversely, a more recent paper could not confirm those findings and 
documented a higher effect of the pan PI3K inhibition in PTEN-deleted T-ALL cell lines147. 
However, both these studies did not take into account PTEN non deleted T-ALL. Indeed, 
PTEN deletions or inactivating gene mutations are rare in primary T-ALL specimens, 
whereas posttranslational inactivation of PTEN is a more frequent event120. In this study 
we have used isoform-selective, pan and dual p110γ/δ inhibitors to compare their effects 
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in both PTEN-deleted and non deleted cell lines. Our results demonstrated that blockage 
of all the class I PI3K catalytic isoforms exert a greater cytotoxic effect compared to the 
dual p110γ/δ inhibition, as exemplified by the lower IC50 reached in all the cell lines, 
whereas isoform-selective inhibition resulted negligible. Among the pan inhibitors, PIK-90 
was effective only in Loucy cells, highlighting that the chemical structure might affect drug 
action. Moreover, the Loucy cell line was the only sensitive to the dual inhibitor IPI-145. 
The peculiar sensitivity of Loucy cells to PI3K pathway inhibition is remarkable, as this cell 
line displays a transcriptional signature similar to that of early T-precursor (ETP)-ALL, a T-
ALL subtype associated with an extremely poor prognosis190. Moreover, only pan-inhibition 
strongly impair leukemic T-cell proliferation. Notably, we did not observe differences 
between PTEN-deleted and non deleted cell lines. Indeed, despite the expression of PTEN 
protein, we found that in PTEN-non deleted cells the phosphatase was phosphorylated at 
Ser380 and thus inactivated. This observation highlights the importance of assessing PI3K 
pathway activation in T-ALL rather than PTEN mutations, to evaluate patients prognosis or 
therapeutic interventions. We also observed a decrease of total PtdIns(3,4,5)P3 following 
inhibition of each PI3K catalytic subunit, suggesting that all the PI3K isoforms contribute to 
its synthesis in T-ALL cells. However, effects on PtdIns(3,4,5)P3 did not correlate to 
cytotoxicity. This apparent contradiction might be due to the presence of different 
PtdIns(3,4,5)P3 pools which mediate specific cellular processes, so that reduction of total 
PtdIns(3,4,5)P3 could not reflect correctly impairment of cell proliferation mechanisms
191. 
Regardless of PI3K downstream targets, we observed a downmodulation of the Akt/mTOR 
pathway. Interestingly, only the pan PI3K inhibitior completely switched off Akt signaling, 
as demonstrated by the reduction or complete abrogation of both Thr308 and Ser473 
phosphorylated Akt proteins. It has been previously reported that a limited PI3K activity is 
sufficient to support cell survival and proliferation and, consequently, complete PI3K 
inhibition is required to induce cell death189. Consistently, in spite of changes in cell cycle 
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progression, we observed a significant cell death induction almost exclusively after pan 
PI3K inhibition, with the exception of Loucy cells where the dual inhibition of p110γ/δ was 
also effective. Importantly, we demonstrated that, at least in the case of ZSTK-474 drug, 
the mechanisms involved in cell death are independent of caspases activity as the pan 
caspase inhibitior did not reduce cell death. Different studies have clarified the existence of 
various types of programmed cell death besides apoptosis including autophagy, an 
important catabolic mechanism which can play both a pro-survival or pro-death role192. 
Importantly, PI3K and autophagy pathways are tightly related, as mTORC1 suppresses 
autophagy inhibiting ULK1, and the transcription factor FoxO3, which is inhibited by Akt, 
regulates the expression of a number of autophagy related genes, including LC3, 
GABARAPL1, BNIP3, PIK3C3 and ULK1178,193-194. Our findings demonstrate that activation 
of autophagy can sustain cell survival after PI3K inhibition. In fact, inhibitors that interfere 
with the autophagic process increased the cytotoxic effects of PI3K inhibitors. However, 
autophagy activation was not seen in all T-ALL cell lines, suggesting the influence of a 
more complex cellular background. To address this issue we examined the expression of 
autophagy related genes. No specific expression profiles were observed related to 
autophagy activation or pan PI3K inhibition and overall gene expression of paired samples 
was similar. Nonetheless, inhibition of PI3K specifically modulated few genes that might 
trigger autophagy. While the Loucy cell line showed a higher autophagy gene expression 
profile already at basal level, we observed the upregulation of few analyzed genes in 
Jurkat, ALL-SIL and DND-41 cells. Increase of these transcripts appear to be cell type 
dependent, as ALL-SIL, DND-41 and partially Loucy cells, which activated autophagy after 
pan PI3K inhibition, upregulated numerous genes involved in the formation of 
autophagosomes (DRAM1, GABARAPL1, GABARAPL2, MAP1LC3B, ATG16L2, WIPI1, 
PIK3C), antiapoptotic genes (BCL2) and genes of the unfolded protein response signaling 
(EIF2AK3). Conversely, in Jurkat cells, which did not activate autophagy, gene modulation 
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was affected at a lesser extent and preferentially involved antiproliferative targets, as the 
cell cycle inhibitors CDKN1B and TP53. These observations suggest a role for the PI3K 
pathway in modulating at a transcriptional level the complex relationship between pro- and 
anti-survival signals and ultimately the balance between autophagy and apoptosis. Of 
course, more studies are needed to clarify these relationships. 
In conclusion, we demonstrated the strongest effect of pan PI3K inhibition in both PTEN 
deleted and non deleted T-ALL cell lines. Although dual inhibition of p110γ/δ PI3K 
isoforms could be less toxic with fewer side effects176, its efficacy could be limited only to a 
subset of T-ALL, i.e. ETP-ALL. Moreover, our findings shed light on the protective role of 
autophagy in response to pan PI3K inhibition, supporting the evaluation of a combination 
of autophagy inhibitors and pan PI3K inhibitors. Further investigation will be necessary to 
discriminate the cellular context(s) responsible for autophagy activation. Addressing this 
question will help to understand which T-ALL patients may best benefit from a therapeutic 
strategy involving class I PI3Ks inhibition. 
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